ICG Imaging: Revolutionizing Liver Function Assessment and Precision Resection Planning in Modern Hepatology

Lucy Sanders Jan 12, 2026 561

This article provides a comprehensive analysis of Indocyanine Green (ICG) fluorescence imaging as a pivotal tool for quantitative liver function assessment and surgical planning in hepatobiliary procedures.

ICG Imaging: Revolutionizing Liver Function Assessment and Precision Resection Planning in Modern Hepatology

Abstract

This article provides a comprehensive analysis of Indocyanine Green (ICG) fluorescence imaging as a pivotal tool for quantitative liver function assessment and surgical planning in hepatobiliary procedures. Aimed at researchers and drug development professionals, it explores the foundational pharmacokinetics of ICG, details current methodological applications including real-time imaging and volumetric analysis, addresses common technical and clinical challenges, and critically evaluates its validation against established tests and emerging technologies. The synthesis underscores ICG's dual role as a biomarker for hepatic functional reserve and a surgical navigator, highlighting its implications for improving patient outcomes in liver surgery and pharmaceutical research on liver-targeted therapies.

Understanding ICG: The Pharmacokinetic Foundation of a Vital Liver Function Biomarker

Indocyanine green (ICG) is a water-soluble, anionic tricarbocyanine dye. Upon intravenous injection, it binds rapidly and almost exclusively (>95%) to plasma proteins, primarily albumin and α1-lipoproteins. This binding confines it to the intravascular space, preventing extravasation. ICG is taken up selectively by hepatocytes via organic anion-transporting polypeptides (OATPs) and is excreted unchanged into the bile via the multidrug resistance-associated protein 2 (MRP2), without enterohepatic recirculation. It is not metabolized.

The key pharmacokinetic parameter is the Plasma Disappearance Rate (ICG-PDR), expressed as %/min, and its derived half-life (t1/2). Normal PDR is >18%/min. The retention rate at 15 minutes (ICG-R15) is also used clinically. Clearance is dependent on hepatic blood flow, hepatocellular function, and biliary excretion integrity.

Table 1: Key Pharmacokinetic Parameters of ICG in Healthy Subjects

Parameter Typical Value (Healthy Liver) Clinical Significance
Plasma Disappearance Rate (PDR) 18 - 25 %/min <18%/min indicates impaired liver function.
Half-life (t1/2) 2 - 4 minutes Prolongs with liver dysfunction.
15-min Retention Rate (ICG-R15) <10% >10% indicates impaired excretion.
Protein Binding >95% (Albumin, α1-lipoprotein) Confines dye to vascular space.
Volume of Distribution ~0.05 L/kg (Plasma volume) Reflects intravascular confinement.
Excretion Route 100% biliary, unchanged No renal excretion or metabolism.

Detailed Experimental Protocols

Protocol 1: Measurement of ICG-PDR and R15 via Pulse Densitometry (Bedside/Clinical)

This non-invasive method uses a finger probe to measure the decay of ICG in the blood.

Materials:

  • ICG solution (e.g., 0.25 mg/kg or 0.5 mg/kg body weight)
  • Pulse Densitometry System (e.g., LiMON, Pulsoflex)
  • IV access and sterile syringes
  • Normal saline for flushing

Procedure:

  • Calibrate the pulse densitometry system according to manufacturer instructions. Attach the optical sensor to the patient's finger.
  • Prepare an exact dose of ICG (typically 0.25-0.5 mg/kg). Avoid exposure to light.
  • Via a peripheral or central venous line, rapidly inject the ICG bolus, followed immediately by a saline flush.
  • The system records the initial rise and subsequent decay of ICG concentration in the arterial blood spectrophotometrically (805 nm wavelength).
  • Data acquisition runs for a minimum of 6-10 minutes. The software automatically calculates the PDR (%/min) by applying linear regression to the mono-exponential decay curve of the dye concentration (from 100% to approximately 30%). The ICG-R15 is calculated by extrapolating the concentration at 15 minutes.

Protocol 2: Measurement of ICG Clearance via Blood Sampling (Gold Standard for Research)

This invasive method provides highly accurate plasma concentration data for detailed pharmacokinetic modeling.

Materials:

  • ICG solution
  • Multiple heparinized blood collection tubes
  • Centrifuge
  • Spectrophotometer or HPLC system
  • Timer

Procedure:

  • Establish baseline by collecting a pre-injection blood sample (t=0).
  • Administer a precise IV bolus of ICG (e.g., 0.5 mg/kg).
  • Collect serial blood samples at frequent intervals (e.g., 1, 3, 5, 7, 10, 15, 20 minutes post-injection).
  • Centrifuge samples immediately (3000 rpm, 10 min) to obtain plasma.
  • Measure ICG concentration in plasma:
    • Spectrophotometry: Dilute plasma 1:10 with saline. Measure absorbance at 805 nm (peak for ICG-bound albumin) and subtract absorbance at 900 nm (background). Compare to a standard curve.
    • HPLC: Provides higher specificity, separating ICG from potential degradants.
  • Plot plasma concentration (log scale) versus time. The terminal phase is typically mono-exponential.
  • Calculate:
    • Elimination rate constant (k) = -2.303 × slope of log-linear plot.
    • Half-life (t1/2) = 0.693 / k.
    • PDR (%) = (1 - e^-k) × 100 (for the initial ~3-minute interval, often derived from modeling).
    • Volume of distribution (Vd) = Dose / C0 (extrapolated concentration at t=0).
    • Plasma clearance (Cl) = k × Vd.

Table 2: Comparison of ICG Measurement Methodologies

Method Principle Advantages Disadvantages Best For
Pulse Densitometry Transcutaneous spectrophotometry Non-invasive, real-time, bedside use Sensitive to perfusion, motion artifacts Clinical monitoring, ICU, OR
Blood Sampling + Spectro. Plasma absorbance at 805nm Direct, relatively simple, low-cost Invasive, discontinuous, sample processing Basic research, validation studies
Blood Sampling + HPLC Chromatographic separation High specificity, detects metabolites/degradants Invasive, expensive, complex Advanced PK studies, stability research

Visualization: ICG Transport and Clearance Pathway

ICG_Pathway cluster_PDR PDR Measurement ICG_IV IV Injected ICG Plasma Plasma Compartment (Bound to Albumin) ICG_IV->Plasma Rapid Binding >95% Uptake Hepatocyte Uptake via OATP1B1/B3 Plasma->Uptake Sinusoidal Flow Probe Finger Probe 805 nm Light Plasma->Probe Arterial Concentration Cytosol Hepatocyte Cytosol (No Metabolism) Uptake->Cytosol Energy-Dependent Transport Excretion Biliary Excretion via MRP2 (ABCC2) Cytosol->Excretion Concentration-Driven Bile Bile Duct & Feces Excretion->Bile Unchanged Molecule Decay Exponential Decay [C] = [C0] * e^(-kt) Probe->Decay Absorbance Calc PDR = (1 - e⁻ᵏ) * 100 R15 = [C₁₅]/[C₀] * 100 Decay->Calc Regression

ICG Hepatic Clearance and PDR Measurement

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for ICG Pharmacokinetics Research

Item / Reagent Solution Function / Role in Research Key Considerations for Use
Sterile ICG Powder The active pharmaceutical ingredient for solution preparation. Light- and heat-sensitive. Must be reconstituted fresh with sterile water (no saline, causes precipitation).
Human Serum Albumin (HSA) Solution For creating standardized protein-binding conditions in in vitro experiments. Mimics in vivo binding. Concentration should reflect physiological levels (~40 mg/mL).
OATP/MRP Transfected Cell Lines (e.g., HEK293 expressing OATP1B1, MRP2) To study specific transport mechanisms of ICG uptake and excretion. Enables isolation of individual transporter contributions; requires validation of expression.
HPLC Solvents & Columns (C18 Reverse-Phase) For high-specificity quantification of ICG and detection of potential photodegradants. Mobile phase often is methanol/water with ion-pairing agents (e.g., tetrabutylammonium). Protect from light during analysis.
Standard Spectrophotometer Calibration Kit To ensure accuracy of absorbance measurements at 805 nm. Critical for validating both blood sample and in vitro assay readings.
Pulse Densitometry Calibration Phantom Device-specific calibration tool for non-invasive monitors. Essential for maintaining measurement accuracy across subjects and time, per manufacturer protocol.
Isolated Perfused Rat Liver (IPRL) Setup An ex vivo model to study hepatic ICG clearance without systemic influences. Allows precise control of perfusion flow, composition, and sampling; technically demanding.
Pharmacokinetic Modeling Software (e.g., Phoenix WinNonlin, PKanalix) To calculate non-compartmental and compartmental PK parameters (PDR, k, Vd, Cl, t1/2) from concentration-time data. Essential for robust data analysis beyond simple half-life calculation.

ICG Clearance as a Direct Measure of Hepatocellular Function and Effective Hepatic Blood Flow

This application note supports a thesis investigating the refinement of Indocyanine Green (ICG) clearance kinetics for quantitative liver function assessment. The core thesis posits that integrated analysis of ICG plasma disappearance rate (ICG-PDR) and retention rate (ICG-R15) provides a superior, real-time metric for predicting post-hepatectomy liver failure (PHLF) and optimizing surgical resection margins compared to static volumetric imaging alone. This document details the underlying physiology, contemporary protocols, and analytical methods for employing ICG clearance as a direct, dual-parameter measure of both global hepatocellular function and effective hepatic blood flow (EHBF).

Physiological & Pharmacokinetic Principles

ICG clearance is governed by hepatic hemodynamics and parenchymal function. Upon intravenous injection, ICG binds exclusively to plasma proteins (albumin, lipoproteins). It is taken up exclusively by hepatocytes via organic anion-transporting polypeptides (OATP1B1/B3) without conjugation and excreted 100% into bile via multidrug resistance-associated protein 2 (MRP2). Its clearance is thus flow-dependent at low extraction rates and capacity-dependent in severe dysfunction. The simultaneous measurement of ICG-PDR (primarily reflecting hepatic perfusion) and ICG-R15 (reflecting functional hepatocyte mass and excretory capacity) offers a composite dynamic assessment.

G ICG_Injection IV ICG Injection Plasma_Binding Plasma Binding (Albumin/Lipoproteins) ICG_Injection->Plasma_Binding Hepatic_Uptake Hepatocyte Uptake via OATP1B1/B3 Plasma_Binding->Hepatic_Uptake Biliary_Excretion Biliary Excretion via MRP2 Hepatic_Uptake->Biliary_Excretion Elimination Fecal Elimination Biliary_Excretion->Elimination Blood_Flow Effective Hepatic Blood Flow (EHBF) Blood_Flow->Hepatic_Uptake Influences Function Hepatocellular Function Function->Hepatic_Uptake Determines Capacity Function->Biliary_Excretion Determines Capacity

Title: ICG Metabolism Pathway & Determinants

Quantitative Parameters & Clinical Thresholds

Table 1: Key ICG Clearance Parameters and Interpretive Values

Parameter Formula/Description Normal Range High-Risk Threshold (for Major Resection) Primary Physiological Correlation
ICG-PDR (%/min) Plasma Disappearance Rate (mono-exponential decay constant k x 100) 18-25 %/min < 16-18 %/min Effective Hepatic Blood Flow (EHBF), Cardiac Output
ICG-R15 (%) Retention Rate at 15 minutes < 10% > 20% Functional Hepatocyte Mass, Excretory Capacity
ICG-CL (mL/min/kg) Plasma Clearance = Dose / AUC₀–∞ ~8-12 mL/min/kg Decreased Composite of Flow and Function
EHBF (mL/min/kg) Effective Hepatic Blood Flow (Model-dependent) ~15-20 mL/min/kg Significantly Decreased Hepatic Perfusion

Detailed Experimental Protocols

Protocol 4.1: Bedside Transcutaneous Pulse Densitometry (e.g., LiMON)

This non-invasive method is standard for perioperative real-time assessment.

A. Materials & Pre-Measurement

  • Subject: Fasted (≥6 hrs) to minimize splanchnic blood flow variations.
  • ICG Solution: Prepare 0.25-0.5 mg/kg body weight (standard: 0.5 mg/kg) in sterile water for injection. Shield from light.
  • Device: Calibrated pulse densitometer with finger or nasal optical sensor.
  • Environment: Stable ambient light, patient at rest, stable hemodynamics.

B. Procedure

  • Place optical sensor on finger. Ensure stable plethysmography signal.
  • Establish baseline for 1-2 minutes.
  • Administer ICG bolus via central or large peripheral vein, followed by 10 mL saline flush.
  • Start continuous measurement on the device. Record for at least 15-20 minutes.
  • The device software automatically calculates and displays real-time ICG-PDR (%/min) and ICG-R15 (%) based on the derived plasma concentration decay curve.

C. Data Analysis

  • The device internally fits the decay curve (typically from ~2-3 minutes post-injection) to a mono-exponential function: C(t) = C₀ * e^(-kt), where k is the disappearance constant.
  • ICG-PDR = k * 100.
  • ICG-R15 is interpolated from the curve at t=15 min.

Protocol 4.2: Gold-Standard Plasma Sampling Method

This invasive method provides definitive validation data for research.

A. Materials

  • ICG Solution: Precisely weighed dose (e.g., 0.5 mg/kg).
  • Blood Collection: Venous catheters (separate for injection and sampling), heparinized/serum tubes, ice.
  • Centrifuge & Spectrophotometer/Fluorometer.
  • Albumin Solution: For standard curve (if using fluorometry).

B. Procedure

  • Baseline Sample: Draw 5 mL blood pre-injection.
  • ICG Administration: Inject exact ICG dose intravenously. Record time = 0.
  • Timed Blood Sampling: Draw 3-5 mL samples at precisely: 2, 4, 6, 8, 10, 12, 15, and 20 minutes post-injection. Keep samples on ice, protected from light.
  • Processing: Centrifuge samples promptly (3000 rpm, 10 min, 4°C). Separate plasma.
  • Quantification:
    • Spectrophotometry: Measure absorbance of diluted plasma at 805 nm (ICG peak) and 900 nm (background turbidity correction). Use a standard curve in pooled human plasma/albumin.
    • Fluorometry (more sensitive): Excitation ~780 nm, Emission ~830 nm. Use a standard curve in 1% human albumin.

C. Data Analysis

  • Correct for background using the 900 nm reading or blank plasma.
  • Plot natural log of plasma ICG concentration vs. time.
  • Fit the linear phase (typically from 2-3 min onward) to determine slope -k.
  • Calculate: ICG-PDR = k * 100.
  • Calculate ICG-R15: Extrapolate concentration at t=15 min from the fitted line: C₁₅ = C₀ * e^(-k*15). Then, ICG-R15 (%) = (C₁₅ / C₀) * 100. C₀ is obtained by back-extrapolation of the slope to t=0.
  • Calculate EHBF using the model of Caesar et al.: EHBF = k * V_d, where V_d (volume of distribution) is approximated as plasma volume (~50 mL/kg).

H cluster_1 Experimental Workflow Start Subject Preparation (Fasted, Stable) A ICG Dose Prep & Baseline Blood Draw Start->A B Bolus IV Injection (Time = 0) A->B C Serial Timed Blood Sampling B->C D Plasma Separation (Centrifuge, 4°C) C->D E ICG Quantification (Spectro/Fluorometry) D->E F Data Fitting & Kinetic Analysis E->F End Output: PDR, R15, EHBF F->End

Title: ICG Plasma Sampling Protocol Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for ICG Clearance Research

Item Function & Specification Research Considerations
Medical-Grade ICG Diagnostic dye for injection. High purity (>95%) is critical for consistent pharmacokinetics. Source from GMP-compliant suppliers. Protect from light and moisture. Prepare fresh solution.
Pulse Densitometer System Non-invasive, real-time monitoring via optical density changes in pulsatile blood. Systems like LiMON (Pulsion) or ICG-ONE (DDG). Essential for intraoperative, repeated measures. Validate against plasma methods.
Fluorometer with NIR Optics High-sensitivity detection of ICG in plasma samples. Excitation ~780 nm, Emission ~830 nm. Superior sensitivity to spectrophotometry for low-concentration or research samples (e.g., rodent studies).
Human Serum Albumin (HSA) For preparing standard curves in ex vivo quantification. Mimics in vivo protein binding. Use fatty acid-free HSA. Standard curve matrix should match sample matrix.
Precision Vascular Catheters For accurate, timed blood sampling in human/animal studies. Minimize dead volume. Use separate lines for injection and sampling to avoid contamination.
Pharmacokinetic Analysis Software For nonlinear curve fitting and compartmental modeling (e.g., Phoenix WinNonlin, PKanalix, or custom scripts in R/Python). Enables calculation of complex parameters (AUC, Vd, CL, EHBF) and statistical comparison between cohorts.

Within research on liver function assessment and resection planning, Indocyanine Green (ICG) has evolved from a simple blood clearance metric to a dynamic, multi-parametric imaging agent. This evolution underpins a modern thesis: that real-time ICG fluorescence imaging provides a superior, spatially-resolved quantification of hepatic functional reserve and oncologic margins, moving beyond global liver function to guide precise surgical and pharmacological interventions.

The application of ICG has progressed through distinct technological phases, each expanding its quantitative output.

Table 1: Evolution of ICG Testing Modalities

Era Primary Modality Key Quantitative Parameter(s) Clinical/Research Insight Provided Spatial Resolution
1960s-1990s Serial Blood Sampling (Photodensitometry) Plasma Disappearance Rate (PDR, %/min), Retention Rate at 15 min (ICG-R15, %) Global liver excretory function. Prognostic for cirrhosis/hepatectomy. None (Whole-organ)
2000s-2010s Pulse Densitometry (Transcutaneous) PDR, Effective Hepatic Blood Flow (EHBF) Non-invasive, real-time global function. Bedside monitoring utility. None (Whole-organ)
2010s-Present Quantitative Fluorescence Imaging (Laparoscopic/Open) Maximum Fluorescence Intensity (Fmax), Time-to-Maximum (Tmax), Removal Rate (RR), Blood Flow Index (BFI) Regional/segmental function mapping, perfusion assessment, tumor visualization. High (Pixel-level)

Table 2: Representative ICG Clearance Values in Liver Research

Liver Status ICG-PDR (Normal: >18 %/min) ICG-R15 (Normal: <10%) Typical Use in Resection Planning
Healthy Liver 18 - 25 %/min < 10% Safe for extended resection (>70%)
Compromised Cirrhosis (Child-Pugh B) 8 - 15 %/min 20 - 50% Limited resection only (<30%)
Post-Major Resection (Future Liver Remnant) Target > 10-12 %/min (post-op) Target < 20% (post-op) Predictive of post-hepatectomy liver failure

Detailed Experimental Protocols

Protocol 1: Traditional Blood Sampling for ICG-R15 & PDR

  • Objective: Determine global liver function via plasma clearance kinetics.
  • Reagents: ICG (25 mg vial), sterile water for injection.
  • Procedure:
    • Prepare a 5 mg/mL ICG solution. Calculate dose (0.5 mg/kg body weight).
    • Adminstrate ICG as a rapid intravenous bolus via a peripheral vein.
    • Collect blood samples (e.g., 2-3 mL) from a different venous access at time points: pre-injection (blank), 5, 10, 15, and 20 minutes post-injection.
    • Centrifuge samples immediately (1500 x g, 10 min) to obtain plasma.
    • Measure absorbance of each plasma sample at 805 nm (ICG peak) and 900 nm (reference) using a spectrophotometer.
    • Calculate corrected absorbance: A_corr = A805 - A900. Plot against time.
    • ICG-R15: Calculate percentage of ICG remaining at 15 min relative to theoretical initial concentration (obtained by back-extrapolation of the clearance curve to time zero).
    • PDR: Calculate from the mono-exponential decay slope of the initial clearance phase (typically 5-15 min), expressed as percentage decrease per minute.

Protocol 2: Real-Time Intraoperative ICG Fluorescence Imaging for Resection Planning

  • Objective: Visualize liver segments, assess regional function, and identify tumors.
  • Reagents: ICG (25 mg vial), sterile water for injection.
  • Equipment: Near-infrared (NIR) fluorescence imaging system (e.g., Karl Storz IMAGE1 S, Stryker 1688, or similar).
  • Procedure – Metabolic Mapping (Pre-Resection):
    • Preoperative: The day before surgery, administer a low-dose ICG bolus (0.5 mg/kg) intravenously.
    • Intraoperative: After laparotomy/laparoscopy, switch the camera system to NIR fluorescence mode.
    • A homogeneous fluorescence pattern indicates normal function. Decreased or absent fluorescence in a specific segment indicates impaired function or vascular occlusion, critical for planning resection boundaries.
  • Procedure – Tumor Delineation & Real-Time Clearance Kinetics:
    • Intraoperative: After liver mobilization, administer a standard dose of ICG (0.25-0.5 mg/kg) intravenously.
    • Imaging Sequence: The NIR camera records continuously.
      • Vascular Phase (0-3 min): Visualize hepatic arterial and portal venous flow.
      • Parenchymal Phase (3-10 min): Liver parenchyma fluoresces uniformly.
      • Biliary Phase (>10 min): ICG excreted into bile ducts. Hepatocellular carcinomas (well-differentiated) appear as fluorescent lesions; most metastases appear as hypo-fluorescent "black holes" against a fluorescent background.
    • Quantitative Analysis (using system software): Place Regions of Interest (ROIs) over different liver segments. The software generates time-intensity curves, calculating Tmax, Fmax, and RR for each ROI, creating a functional map.

Visualizing the Workflow & Mechanism

ICG_Workflow cluster_mod Historical Evolution of Modalities Start IV Bolus of ICG Blood Binding to Plasma Proteins (Albumin, Lipoproteins) Start->Blood Liver1 Hepatocyte Uptake via OATP1B3 Blood->Liver1 Modality Measurement Modality Blood->Modality Vascular Phase Liver2 Intracellular Storage (No Conjugation) Liver1->Liver2 Liver1->Modality Parenchymal Phase Liver3 Biliary Excretion via MRP2 Liver2->Liver3 End Fecal Elimination Liver3->End Liver3->Modality Biliary Phase Data Quantitative Data Output Modality->Data M1 Serial Blood Sampling M2 Pulse Densitometry M3 Quantitative NIR Imaging

Title: ICG Pharmacokinetics & Measurement Evolution

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for ICG Liver Function Research

Item Function & Research Application
Indocyanine Green (ICG), Sterile The inert, fluorescent tracer. Purity is critical for consistent pharmacokinetics and fluorescence yield.
Human Serum Albumin (HSA) Used in in vitro studies to replicate ICG-protein binding, crucial for studying uptake kinetics.
OATP1B3 & MRP2 Transfected Cell Lines In vitro models to study specific transporter-mediated uptake (OATP1B3) and excretion (MRP2) of ICG.
Standardized Fluorescence Phantom Essential for calibrating NIR imaging systems, enabling quantitative, reproducible fluorescence intensity measurements across studies.
Near-Infrared Fluorescence Imaging System Includes laser/excitation source (∼780 nm), NIR-sensitive camera, and quantitative analysis software for real-time imaging.
Spectrophotometer / Pulse Densitometer For traditional plasma clearance (PDR, R15) measurement, serving as the historical gold standard for validation.
Pharmacokinetic Modeling Software (e.g., Phoenix WinNonlin) To model ICG clearance curves and derive advanced parameters beyond PDR.

The Cellular and Molecular Basis of ICG Uptake by Hepatocytes and Its Clinical Correlation

Indocyanine green (ICG), a water-soluble tricarbocyanine dye, is exclusively taken up by hepatocytes and excreted unchanged into bile. This unique pharmacokinetic profile underpins its clinical utility for liver function assessment and surgical guidance. The process is governed by specific sinusoidal membrane transporters, primarily the organic anion-transporting polypeptides (OATPs), with intracellular binding and storage mediated by glutathione S-transferases (GSTs) and subsequent canalicular excretion via the multidrug resistance-associated protein 2 (MRP2/ABCC2). This application note details the molecular mechanisms, provides experimental protocols for in vitro and ex vivo investigation, and correlates these findings with quantitative clinical metrics for resection planning.

Molecular Transporters and Binding Proteins

The hepatobiliary transit of ICG is a multi-step process facilitated by specific transporters and proteins.

Key Transporters and Proteins
Protein Gene Symbol Cellular Location Primary Function in ICG Kinetics Inhibition/Competition
OATP1B1 SLCO1B1 Basolateral (Sinusoidal) Membrane Primary uptake transporter. Mediates sodium-independent uptake. Rifampicin, Cyclosporin A, Bromosulfophthalein (BSP)
OATP1B3 SLCO1B3 Basolateral (Sinusoidal) Membrane Secondary uptake transporter. Contributes to overall hepatic extraction. Rifampicin, Cyclosporin A, BSP
NTCP SLC10A1 Basolateral Membrane Minor role; primarily for bile acids. Likely negligible for clinical ICG doses. Taurocholate
Glutathione S-transferase GST family Cytosol Intracellular binding and sequestration, prevents reflux. Ethacrynic acid
MRP2 ABCC2 Canalicular Membrane ATP-dependent excretion into bile. Cyclosporin A, MK-571
MDR3 ABCB4 Canalicular Membrane Phosphatidylcholine flippase; indirect role in bile formation and ICG excretion. -
Quantitative Kinetic Data

Table 1: Representative Pharmacokinetic Parameters of ICG in Healthy Human Liver.

Parameter Typical Value Physiological/Clinical Correlation
Plasma Disappearance Rate (PDR) 18-25 %/min Global liver function; <15-17%/min indicates significant impairment.
Retention Rate at 15 min (ICG-R15) <10% Standardized index of excretory function; critical for resection planning (e.g., safe limit often set at <14%).
Hepatic Extraction Fraction ~70-90% on first pass High efficiency due to OATP activity.
Time to Peak Excretion in Bile ~20-30 minutes Reflects combined uptake, intracellular transit, and MRP2-mediated excretion.
Protein Binding (Albumin) ~95% Ensures vascular confinement and directs delivery to hepatocyte transporters.

Experimental Protocols

Protocol 1:In VitroICG Uptake Assay in Transfected Cells

Purpose: To characterize the specific contribution of OATP1B1/1B3 to ICG uptake. Materials:

  • HEK293 or MDCK-II cells stably expressing human OATP1B1 or OATP1B3.
  • Control cells (empty vector).
  • HBSS buffer (pH 7.4).
  • ICG stock solution (1 mM in DMSO, store in dark, -20°C).
  • Cyclosporin A (10 µM in HBSS) for inhibition control.
  • 24-well cell culture plates.
  • Fluorescence plate reader (ex/em: ~780/820 nm) or spectrophotometer (805 nm absorbance).

Procedure:

  • Seed cells in 24-well plates at 2.5 x 10^5 cells/well. Culture for 48h to reach confluence.
  • Aspirate medium and wash cells twice with pre-warmed HBSS.
  • Pre-inhibition (optional): Incubate designated wells with 250 µL of 10 µM Cyclosporin A in HBSS for 15 min at 37°C.
  • Uptake Phase: Add 250 µL of HBSS containing 5 µM ICG (with or without inhibitor) to each well. Incubate at 37°C for 5 minutes.
  • Termination: Rapidly aspirate the ICG solution and wash cells three times with ice-cold HBSS.
  • Lysis: Lyse cells with 250 µL of 1% Triton X-100 in PBS for 30 min at room temperature with gentle shaking.
  • Quantification: Transfer 200 µL of lysate to a black-walled 96-well plate. Measure ICG fluorescence/absorbance. Normalize total protein content via BCA assay.
  • Analysis: Calculate specific uptake by subtracting values from vector-control cells. Express as pmol ICG/mg protein/min.
Protocol 2:Ex VivoICG Uptake and Clearance in Precision-Cut Liver Slices (PCLS)

Purpose: To assess integrated hepatocellular uptake and biliary excretion in a near-physiological tissue architecture. Materials:

  • Fresh liver tissue (human or animal).
  • Krumdieck tissue slicer.
  • Williams' Medium E with supplements.
  • ICG solution (prepared in medium).
  • Custom perfusion chamber or multi-well plate on a rocker.
  • Confocal microscopy system with NIR detection capability.

Procedure:

  • Prepare PCLS (~200-300 µm thickness, 5-8 mm diameter) in ice-cold, oxygenated preservation buffer.
  • Recover slices in oxygenated Williams' Medium E at 37°C for 1h.
  • Transfer slices to a chamber with 10 µM ICG in medium. Continuously oxygenate (95% O2 / 5% CO2).
  • Image live slices using confocal microscopy at 785 nm excitation every 2-5 minutes for up to 60 min to track intracellular accumulation.
  • For clearance assessment, after 20 min of loading, transfer slices to ICG-free medium and continue imaging to monitor efflux.
  • Quantification: Analyze mean fluorescence intensity (MFI) in region-of-interest (ROI) drawn over hepatocyte areas. Generate time-activity curves for uptake and clearance phases.

Diagrams of Signaling Pathways and Workflows

ICG_Pathway ICG_Albumin ICG-Albumin Complex OATP OATP1B1/1B3 ICG_Albumin->OATP Sinusoidal Uptake Cytosol Cytosol OATP->Cytosol ICG Influx GST GST Binding Cytosol->GST Sequestration MRP2 MRP2/ABCC2 GST->MRP2 Delivery Bile Bile Canaliculus MRP2->Bile ATP-dependent Excretion

Title: Molecular Pathway of ICG Hepatobiliary Transit

PCLS_Workflow Liver Fresh Liver Tissue Slice Generate PCLS (200-300 µm) Liver->Slice Recover Recovery Incubation 1h, 37°C, O2 Slice->Recover Load ICG Loading Phase (10 µM, 20 min) Recover->Load Image1 Live Imaging (Uptake Phase) Load->Image1 Wash Transfer to ICG-free Medium Image1->Wash Image2 Live Imaging (Clearance Phase) Wash->Image2 Analysis Quantitative Fluorescence Analysis Image2->Analysis

Title: Ex Vivo ICG Uptake/Clearance in PCLS Workflow

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for ICG Hepatocyte Uptake Research.

Item / Reagent Function / Application Key Note
Clinical-Grade ICG (PULSION) Gold standard for in vivo human studies and calibration. Defined molecular weight, purity >95%. For reproducible clinical correlation.
OATP-Transfected Cell Lines (e.g., HEK293-OATP1B1) Isolate and quantify specific transporter activity. Commercially available (e.g., Solvo Biotechnology, Corning). Use with vector-control.
Selective Transport Inhibitors (Cyclosporin A, Rifampicin) Pharmacological blockade to confirm transporter-specific pathways. Validate OATP/MRP2 involvement in uptake/efflux assays.
Precision-Cut Liver Slice (PCLS) System Maintains native tissue architecture and cell polarity for integrated studies. Krumdieck slicer or compresstome. Critical for bile canalicular function studies.
Near-Infrared (NIR) Fluorescence Imaging System Detection of ICG in biological samples (cells, tissues, in vivo). Confocal microscopes with NIR detectors or dedicated clinical systems (e.g., PDE/SPY).
Anti-OATP/MRP2 Antibodies Immunohistochemistry/Western blot to localize and quantify transporter expression. Correlate transporter density with functional uptake data in patient samples.
ICG Fluorescence Standard Curve Kits Quantify absolute ICG concentration in lysates or serum. Essential for converting fluorescence/absorbance to molar values in pharmacokinetic models.

From Assessment to Action: Methodologies for ICG-Guided Liver Function Mapping and Surgical Navigation

Within the broader thesis on indocyanine green (ICG) for liver function assessment, quantitative ICG clearance tests are pivotal. They provide objective, dynamic measures of hepatic functional reserve, surpassing static laboratory parameters. This is critical for two primary research domains: (1) Pre-operative risk stratification and resection planning in hepatic surgery (determining safe future liver remnant volume), and (2) Monitoring liver function in drug development, particularly in trials for hepatotoxic compounds, chemotherapeutic agents, or treatments for chronic liver disease. ICG-R15 (the percentage of ICG retained at 15 minutes) and ICG-PDR (the plasma disappearance rate, %/min) are the cornerstone metrics for this quantitative assessment.

Core Quantitative Data: ICG-R15 and ICG-PDR Interpretation

Table 1: Clinical Interpretation of ICG Clearance Parameters

Parameter Normal Range Mid-Range Impairment High-Risk/ Severe Impairment Primary Clinical/Research Implication
ICG-R15 < 10% 10% - 20% > 20% - 40%+ Direct measure of excretory function retention. >10% often flags significant impairment.
ICG-PDR > 18 %/min 10 - 18 %/min < 10 %/min Dynamic measure of clearance velocity. Correlates with hepatic blood flow and cellular uptake.
Estimated Reference Healthy volunteer cohort Compensated cirrhosis, chemotherapy Decompensated cirrhosis, major hepatectomy risk Values are protocol/device dependent; internal controls are essential.

Table 2: Correlation with Post-Hepatectomy Liver Failure (PHLF) Risk

Pre-operative ICG-R15 Risk Stratification for Major Resection Typical Resection Planning Consideration
< 10% Low Risk Standard volume assessment (e.g., FLR > 20-30%)
10% - 20% Moderate Risk Require larger FLR (e.g., > 30-40%), consider portal vein embolization.
> 20% High Risk Avoid major resection; consider alternative strategies or limited parenchymal-sparing resections.

Experimental Protocols for Quantitative ICG Measurement

Protocol 3.1: Standard Pulse Densitometry Method (Non-Invasive)

This is the most common method in clinical research using devices like the LiMON (Pulsion) or ICG Fingerprint Sensor.

A. Principle: ICG is injected intravenously; its concentration in blood is monitored transcutaneously via an optical sensor placed on the fingertip or nose, using optical densitometry at 805 nm (ICG absorption peak) and 940 nm (reference wavelength).

B. Materials & Pre-Test:

  • Confirm patient fasting status (>2 hours) and stable hemodynamics.
  • Calibrate the pulse densitometry device per manufacturer instructions.
  • Establish intravenous access (preferably central line for high accuracy, peripheral acceptable).
  • Prepare ICG dose: 0.5 mg/kg body weight, dissolved in aqueous solvent (usually provided). Shield from light.

C. Procedure:

  • Place optical sensor on clean, nail-polish-free fingertip.
  • Start baseline measurement for 30-60 seconds to establish stable signal.
  • Bolus Injection: Rapidly inject the prepared ICG dose via IV line, immediately flush with 10-15 mL of normal saline.
  • Data Acquisition: Continuously record the densitometric signal for a minimum of 15-20 minutes. Ensure patient remains still.
  • Calculation: Device software automatically calculates the decay curve, deriving PDR from the linear portion of the semi-logarithmic plot (typically between 2-5 minutes post-injection) and ICG-R15 by extrapolating/interpolating the concentration at t=15 minutes.

Protocol 3.2: Blood Sampling Method (Invasive, Reference Standard)

Used for validation studies or when non-invasive monitoring is unreliable (e.g., poor peripheral perfusion).

A. Principle: Serial blood samples are drawn at precise time points post-ICG injection. Plasma ICG concentration is measured spectrophotometrically.

B. Procedure:

  • Injection: As in Protocol 3.1, administer ICG bolus (0.5 mg/kg).
  • Blood Sampling: Draw 3-5 mL of venous blood into heparinized tubes at the following time points: Pre-injection (blank), and at 5, 10, 15, and 20 minutes post-injection. Timing must be exact.
  • Sample Processing: Centrifuge blood samples promptly (3000 rpm, 10 min). Separate plasma, protect from light.
  • Spectrophotometric Analysis: a. Dilute each plasma sample 1:10 or 1:20 with normal saline or the patient's own blank plasma. b. Measure absorbance at 805 nm (A805) and 900 nm (A900) using a spectrophotometer. c. Calculate corrected ICG absorbance: A_ICG = A805 - A900 (corrects for turbidity and hemoglobin).
  • Data Analysis: a. Plot log(A_ICG) against time. b. Fit a linear regression to the points from 5-20 minutes. c. PDR = (slope * -2.303) * 100, expressed as %/min. d. ICG-R15: From the regression line, calculate the concentration at t=15 min as a percentage of the extrapolated concentration at t=0.

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for ICG Clearance Studies

Item Function & Research Purpose
Lyophilized ICG The fluorescent dye itself. Must be USP grade, reconstituted in provided aqueous solvent (not saline). Light-sensitive.
Pulse Densitometry System (e.g., LiMON, ICG Fingerprint) Enables non-invasive, real-time measurement of plasma ICG concentration for dynamic PDR calculation. Critical for bedside research.
Spectrophotometer (Cuvette-based or microplate) Reference method for quantifying ICG in plasma samples. Requires precision at 805 nm.
Heparinized Blood Collection Tubes Prevents coagulation for plasma separation in the reference sampling method.
Precision Timer Essential for exact timing of post-injection blood draws in Protocol 3.2.
Hemodynamic Monitor To correlate ICG-PDR with mean arterial pressure and cardiac output, as both influence hepatic perfusion.

Visualized Workflows and Pathways

G Start Patient Preparation (Fasting, Stable Hemodynamics) A IV Access & ICG Bolus Injection (0.5 mg/kg) Start->A B Method Selection A->B C1 Non-Invasive Pulse Densitometry B->C1 Clinical/Real-time C2 Invasive Blood Sampling Protocol B->C2 Validation/Precision D1 Sensor Placement (Fingertip/Nose) C1->D1 D2 Serial Blood Draws (at t=5,10,15,20 min) C2->D2 E1 Continuous Optical Measurement (15+ min) D1->E1 E2 Plasma Separation & Spectrophotometry D2->E2 F1 Device Software Analysis: Decay Curve Fitting E1->F1 F2 Calculate Absorbance A_ICG = A805 - A900 E2->F2 G Calculate Key Metrics: ICG-PDR & ICG-R15 F1->G F2->G End Interpretation for Resection Planning / Drug Trial G->End

Title: Quantitative ICG Test Experimental Workflow

G ICG_Injection IV Bolus Injection IntravascularSpace Intravascular Space (Plasma Binding to Proteins) ICG_Injection->IntravascularSpace 1. Distribution HepaticUptake Hepatic Uptake via OATP1B1/B3 Transporters IntravascularSpace->HepaticUptake 2. Active Transport Hepatocyte Hepatocyte (No Conjugation) HepaticUptake->Hepatocyte ICG_PDR ICG-PDR (%/min) Reflects Steps 1-3 HepaticUptake->ICG_PDR Primary Determinant BiliaryExcretion Biliary Excretion via MRP2 Transporter Hepatocyte->BiliaryExcretion 3. Active Export Bile Bile → Feces BiliaryExcretion->Bile 4. Elimination ICG_R15 ICG-R15 (%) Reflects Steps 1-4 BiliaryExcretion->ICG_R15 Key Determinant

Title: ICG Hepatobiliary Pathway & Metric Correlation

This application note details protocols for intraoperative fluorescence imaging (FI) using Indocyanine Green (ICG) in hepatic surgery. Within the broader thesis research on ICG for quantitative liver function assessment and precision resection planning, these methods enable real-time, simultaneous visualization of anatomical and pathological structures. The techniques described directly inform surgical navigation and provide visual data correlating to functional hepatic reserve metrics.

Fundamental Principles and Pharmacokinetics

ICG is a water-soluble, fluorescent tricarbocyanine dye. Following intravenous injection, it binds rapidly to plasma proteins (primarily albumin). It is taken up exclusively by hepatocytes via organic anion-transporting polypeptides (OATPs) and excreted unchanged into the bile via multidrug resistance-associated protein 2 (MRP2). No hepatic metabolism occurs. This predictable pathway enables staged imaging.

Table 1: ICG Pharmacokinetic Parameters for Staged Liver Imaging

Parameter Preoperative (Functional Assessment) Intraoperative (Segmentation) Intraoperative (Biliary Imaging)
ICG Dose 0.5 mg/kg (IV) 2.5 mg (IV, post-dissection) 2.5 - 5.0 mg (IV, 15-60 min pre-op)
Timing to Imaging Plasma clearance measured pre-op (PDR, ICG-R15) Immediate (within 2-5 min) Delayed (30-60+ min post-injection)
Visualized Structure N/A (Quantitative clearance) Hepatic segments (via portal flow) Biliary tree & liver tumors
Mechanism Global hepatocyte uptake & excretion Arterial/Portal Inflow: ICG stains parenchyma Tumor: Enhanced permeability & retention (EPR). Bile: Excretion into canaliculi
Fluorescence Signal N/A Positive (Parenchyma): High Positive (Tumors): High (rim/margin). Bile: High. Parenchyma: Low/Washed-out

Experimental Protocols

Protocol 3.1: Preoperative Quantitative Liver Function Assessment (ICG Clearance Test)

Purpose: To determine the ICG plasma disappearance rate (PDR) and retention rate at 15 minutes (ICG-R15) for resection planning. Materials: ICG powder, sterile water, spectrophotometer or dedicated bedside monitor (e.g., LiMON, Pulsoflex). Procedure:

  • Prepare a 5 mg/mL ICG solution using sterile water.
  • Calculate dose (0.5 mg/kg of patient body weight). Draw into syringe.
  • Administer ICG as a rapid intravenous bolus via a central or large peripheral vein.
  • For Pulse Densitometry (LiMON): Attach sensor to patient's fingertip. The device automatically records the dye dilution curve for 15+ minutes, calculating PDR (%/min) and ICG-R15 (%).
  • For Blood Sampling: Draw venous blood samples at 0 (pre), 5, 10, 15, and 20 minutes post-injection. Centrifuge to obtain plasma.
  • Measure plasma ICG concentration spectrophotometrically at 805 nm (absorbance peak). Fit data to a mono-exponential decay curve.
  • Interpretation: PDR < 18%/min or ICG-R15 > 10% indicates significantly impaired hepatic functional reserve, prompting caution in major resection.

Protocol 3.2: Intraoperative Liver Segmentation (Positive Staining Technique)

Purpose: To visually demarcate hepatic segments or subsegments for guided anatomical resection. Procedure:

  • After Laparotomy & Mobilization: Complete dissection and control of the inflow vasculature (portal vein, hepatic artery) to the target segment(s) to be resected.
  • ICG Administration: Inject a low dose (e.g., 2.5 mg) of ICG intravenously as a bolus.
  • Imaging: Switch the fluorescence imaging system (e.g., PINPOINT, FLUOBEAM, or similar) to near-infrared (NIR) mode immediately.
  • Observation: The perfused hepatic parenchyma will fluoresce brightly within 30-60 seconds. The ischemic segment(s) with interrupted inflow will remain dark, providing a clear "negative-stain" or "positive-stain" demarcation line on the liver surface.
  • Resection Guidance: Transect the liver parenchyma along this fluorescent boundary.

Protocol 3.3: Intraoperative Tumor and Biliary Tree Imaging

Purpose: To detect subcapsular/occult tumors and visualize the extrahepatic biliary anatomy to avoid injury. Procedure:

  • Preoperative Dosing: Administer 2.5 mg ICG intravenously 15-60 minutes before scheduled laparotomy (timing requires optimization based on liver function).
  • Tumor Detection (During Laparotomy): Use the NIR fluorescence camera to survey the liver surface and, if possible, using intraoperative ultrasound, the parenchyma. Malignant tumors (HCC, metastases) typically appear as hypofluorescent (dark) defects against a fluorescent background due to absent hepatocyte function. Some metastases (e.g., colorectal) may show a hyperfluorescent rim due to the EPR effect.
  • Biliary Imaging (Critical View of Safety): After 30-60 minutes, ICG is excreted into the biliary system. The extrahepatic bile ducts (cystic duct, common bile duct) will fluoresce brightly. This aids in identifying anatomy during cholecystectomy and preventing bile duct injury. The gallbladder may also fluoresce.

Protocol 3.4: Ex Vivo & Specimen Imaging

Purpose: To assess resection margins and tumor multiplicity on the explanted specimen. Procedure:

  • After resection, place the liver specimen under the NIR fluorescence camera.
  • Examine the cut surface. Tumor margins: A dark (non-fluorescent) tumor should be surrounded by a fluorescent parenchymal rim. A margin < 5 mm may be concerning.
  • Document any additional fluorescent or hypofluorescent nodules not identified preoperatively.

Signaling Pathways and Workflows

G node1 IV ICG Injection node2 Binding to Plasma Proteins (Primarily Albumin) node1->node2 node3 Hepatocyte Uptake via OATP Transporters node2->node3 node6 Vascular Phase (0-5 min post-IV) node2->node6 Timing node4 Intracellular Transport node3->node4 node7 Parenchymal Phase (5-90 min post-IV) node3->node7 node5 Excretion into Bile via MRP2 Transporter node4->node5 node8 Biliary Phase (>60 min post-IV) node5->node8 node9 Imaging Application node6->node9 node7->node9 node8->node9 node10 Segmentation (Positive Stain) node9->node10 node11 Tumor Detection (Negative Stain/Rim) node9->node11 node12 Bile Duct Visualization node9->node12

Title: ICG Pharmacokinetic Pathway and Imaging Phases

G start Preoperative Planning p1 ICG-R15/PDR Test (0.5 mg/kg IV) start->p1 dec1 ICG-R15 > 10%? PDR < 18%/min? p1->dec1 op1 Modify Resection Plan (Smaller Volume) dec1->op1 Yes p2 Tumor-Marking Dose (2.5 mg IV, 60 min pre-op) dec1->p2 No op1->p2 int Intraoperative Phase p2->int p3 Intraoperative Segmentation (2.5 mg IV post-dissection) step3 NIR Segmentation (Fluorescent Demarcation) p3->step3 step1 NIR Survey for Tumors (Hypofluorescence) int->step1 step2 Portal Dissection & Target Vessel Control step1->step2 step2->p3 step4 Parenchymal Transection Along Fluorescent Line step3->step4 step5 NIR Check of Specimen Margin & Bile Duct Stump step4->step5

Title: Integrated Surgical Workflow Using ICG-FI

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for ICG-based Liver FI Research

Item / Reagent Function / Role in Research Example / Note
ICG for Injection The fluorescent tracer agent. Must be pure, sterile, and prepared fresh. Verdye (Diagnostic Green), Pulsion (standard clinical source). Research-grade ICG powder also available.
NIR Fluorescence Imaging System Captures emitted fluorescence (approx. 830 nm) against ambient light. Open-field systems: Stryker PINPOINT, Karl Storz VITOM, Fluoptics FLUOBEAM. Laparoscopic: Olympus/EVIS, Zeiss Pentero.
Quantitative ICG Monitor Measures plasma ICG concentration non-invasively for kinetic analysis. LiMON (Pulsion Medical Systems), Pulsoflex (PV2025 LiDCO) – calculates PDR & R15.
Spectrophotometer & Cuvettes For in vitro quantification of ICG concentration in plasma/serum samples. Measure absorbance at 805 nm. Requires standard curve for quantification.
Small Animal Imaging System For preclinical pharmacokinetic and tumor model studies. PerkinElmer IVIS Spectrum, Carestream MS FX Pro with NIR filters.
Image Analysis Software Quantifies fluorescence intensity, tumor-to-liver ratio (TLR), signal kinetics. ImageJ/FIJI (with NIR plugins), proprietary software from imaging system vendors.
Hepatocyte & Biliary Cell Cultures In vitro models to study uptake (OATP) and excretion (MRP2) mechanisms. Primary human hepatocytes, HepaRG cells, sandwich-culture models for biliary excretion.
Tumor Xenograft Mouse Models To study the EPR effect and tumor detection thresholds. Subcutaneous or orthotopic models (e.g., Huh7 for HCC, HT-29 for CRC mets).
Organ Perfusion Systems (ex vivo) To study segmental staining techniques and perfusion kinetics. Machine perfusion systems for human/large animal livers.

Within the broader thesis investigating quantitative dye elimination tests for hepatic resection planning, the prediction of Post-Hepatectomy Liver Failure (PHLF) remains paramount. PHLF is the leading cause of mortality following major hepatectomy. Traditional volumetric assessment via CT or MRI is necessary but insufficient, as it fails to account for the functional heterogeneity of the parenchyma, especially in patients with underlying liver disease. Indocyanine Green (ICG) clearance testing provides a dynamic, quantitative measure of global liver function and regional functional reserve. Integrating ICG metrics with volumetric data enables a more robust prediction of PHLF risk, guiding surgical strategy towards safer margins.

Key ICG-Derived Parameters & Predictive Metrics

ICG is a water-soluble anionic tricarbocyanine dye exclusively taken up by hepatocytes and excreted unchanged into bile. Its pharmacokinetics after intravenous injection are used to calculate several functional indices.

Table 1: Core ICG Pharmacokinetic Parameters and Calculations

Parameter Formula/Description Typical Units Functional Significance
ICG R15 Retention rate at 15 minutes post-injection. % Direct clinical marker. >10-15% indicates impaired excretion, high PHLF risk.
Plasma Disappearance Rate (ICG-PDR) Percentage decrease in concentration per minute, derived from mono-exponential decay. %/min <18%/min correlates with significant dysfunction.
Effective Hepatic Blood Flow (EHBF) Derived from ICG clearance and hematocrit. mL/min Estimates functional hepatic perfusion.
ICG Clearance (ICG-K) Elimination rate constant from plasma. min⁻¹ Reciprocal of the elimination half-life.
ICG Retention at 5 min (ICG-R5) Used in some protocols (e.g., LiMON). % Alternative early retention marker.

Table 2: Combined Volumetric-Functional Indices for PHLF Prediction

Index Calculation Predictive Threshold (Example) Rationale
Future Liver Remnant Volume (FLRV) CT Volumetry: Total liver volume – tumor volume. mL, %TLV Pure anatomic measure.
Future Liver Remnant Function (FLRF) FLRV (%) × (1 – ICG-R15) or FLRV × ICG-PDR. Variable Integrates function of remnant tissue.
ICG Clearance of FLR FLRV × ICG-K. mL/min Estimates total eliminatory capacity of the remnant.
Hybrid Score (e.g., ALICE) Combines ICG-R15, FLR%, and biomarkers. Score > cutoff Multifactorial risk assessment.

Detailed Experimental Protocols

Protocol 3.1: Pulse Densitometry (Non-Invasive) ICG Measurement

This method, used by devices like the LiMON (Pulsion) or Dextin-01, is standard in clinical research.

A. Primary Reagents & Equipment

  • ICG (Diagnostic Green, 25mg vial): The inert, non-radioactive fluorescent tracer.
  • ICG Pulse Densitometer: Device with finger probe emitting LED light at 805 nm (absorption max of ICG) and 940 nm (isosbestic reference).
  • Sterile Water for Injection (5mL ampoule): Solvent for ICG.
  • Intravenous Cannula & Syringes: For bolus injection and blood sampling (if required for calibration).
  • Data Acquisition Software: Provided with the device.

B. Pre-Test Conditions

  • Obtain informed consent (IRB-approved).
  • Patient fasts for 6-8 hours. Maintain supine position for 15 min prior to and during test.
  • Record patient weight, height, and hematocrit (for PDR/clearance calculation).
  • Calibrate the finger probe according to manufacturer instructions.

C. Test Procedure

  • ICG Preparation: Reconstitute 25mg ICG powder in 5mL sterile water (5 mg/mL). Protect from light. Use immediately.
  • Baseline Measurement: Record a stable baseline densitometric signal for 60 seconds.
  • ICG Administration: Inject a bolus of 0.5 mg ICG per kg body weight via a peripheral vein, followed by a 10mL saline flush. Start data recording simultaneously.
  • Data Recording: Monitor the densitometric curve continuously for 15-20 minutes. Ensure no patient movement.
  • Data Analysis: Software automatically calculates ICG-PDR (%) and ICG-R15 (%) via a mono-exponential fit of the decay curve: C(t) = C₀ × e^(-K × t), where PDR = K × 100.

Protocol 3.2: Blood Sampling-Based ICG Clearance

The gold-standard reference method, used for validation or when non-invasive devices are unavailable.

A. Primary Reagents & Equipment

  • ICG (as above).
  • Spectrophotometer or Fluorometer.
  • Heparinized or EDTA Blood Collection Tubes.
  • Centrifuge.
  • Saline or Plasma for Calibration Standards.

B. Calibration Curve Preparation

  • Prepare an ICG stock solution (e.g., 10 µg/mL) in phosphate-buffered saline (PBS) or drug-free plasma.
  • Perform serial dilutions to create standards (e.g., 0, 0.5, 1, 2, 5 µg/mL).
  • Measure absorbance at 805 nm (or fluorescence at Ex/Em ~780/830 nm). Plot concentration vs. absorbance/fluorescence.

C. Test Procedure

  • ICG Injection: As in Protocol 3.1.
  • Blood Sampling: Draw 2-3 mL blood samples at precise times: Pre-injection (blank), and at 2, 4, 6, 8, 10, 12, 15 minutes post-injection.
  • Sample Processing: Centrifuge blood samples promptly at 1500 g for 10 min. Separate plasma.
  • Concentration Measurement: Dilute plasma samples if necessary and measure absorbance/fluorescence against the calibration curve.
  • Pharmacokinetic Analysis: Fit plasma concentration-time data to a mono-exponential decay model using software (e.g., Phoenix WinNonlin, PKAnalyst). Calculate K, half-life (t₁/₂ = ln2/K), and R15 via interpolation.

Protocol 3.3: Integration with CT Volumetry for Risk Stratification

  • Perform Preoperative CT/MRI: Acquiate contrast-enhanced images in portal venous phase.
  • Volumetric Analysis: Use semi-automatic segmentation software (e.g., Synapse Vincent, OsiriX, 3D Slicer) to delineate:
    • Total Liver Volume (TLV): Excluding tumor volume.
    • Future Liver Remnant (FLR) Volume: The segments to remain after planned resection.
    • Calculate FLR%: (FLRV / TLV) × 100.
  • Perform ICG Test: As per Protocol 3.1 or 3.2.
  • Calculate Composite Indices: Compute FLRF or ICG clearance of FLR (see Table 2).
  • Risk Stratification: Apply validated cutoff values (e.g., for cirrhotics: FLR% <40% with ICG-R15 >10% signifies very high risk).

Visualization of Concepts & Workflows

G Patient Patient ICG_Injection ICG_Injection Patient->ICG_Injection IV Bolus CT_MRI CT_MRI Patient->CT_MRI Imaging Measurement Measurement ICG_Injection->Measurement Dye Kinetics Data Data Measurement->Data [ICG] vs. Time PK_Params PK_Params Data->PK_Params Monte Carlo Fit IntegrativeModel IntegrativeModel PK_Params->IntegrativeModel ICG-R15/PDR Volumetry Volumetry CT_MRI->Volumetry Segmentation FLR_Volume FLR_Volume Volumetry->FLR_Volume FLR% FLR_Volume->IntegrativeModel FLR Volume PHLF_Risk PHLF_Risk IntegrativeModel->PHLF_Risk Predicts

ICG & Imaging Integrated PHLF Risk Assessment

G ICG_Molecule ICG Molecule IV Injection Plasma_Compartment Plasma Compartment ICG_Molecule->Plasma_Compartment Hepatocyte_Uptake Hepatocyte Uptake via OATP1B3 Plasma_Compartment->Hepatocyte_Uptake Carrier-Mediated Intracellular Intracellular Space Hepatocyte_Uptake->Intracellular Canalicular_Excretion Canalicular Excretion via MRP2 Intracellular->Canalicular_Excretion ATP-Dependent Bile Bile Elimination Canalicular_Excretion->Bile Liver_Disease Chronic Liver Disease (Fibrosis, Cholestasis) Liver_Disease->Hepatocyte_Uptake Reduces Liver_Disease->Canalicular_Excretion Reduces

ICG Hepatobiliary Transit Pathway

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for ICG Liver Function Research

Item Function & Rationale Example/Supplier Notes
ICG, Sterile, Lyophilized The essential inert tracer for hepatic uptake and excretion studies. Must be protected from light. Diagnostic Green, Inc. (USA); PULSION Medical (Germany). Standard 25mg vials.
Non-Invasive ICG Monitor Enables real-time, repeated measurements without blood draws, ideal for kinetic studies and patient cohorts. LiMON (Pulsion), Dextin-01 (Daitchi). Measures via pulse densitometry.
Spectrophotometer / Plate Reader For quantifying ICG concentration in plasma/serum samples in batch analysis for PK validation. Requires capability at 805 nm (absorbance) or 780/830 nm (fluorescence).
Pharmacokinetic Analysis Software To model ICG decay curves, calculate PDR, K, half-life, and AUC with precision. Phoenix WinNonlin, PKAnalyst, R with nlmixr/PK packages.
Medical Imaging Segmentation Software For precise calculation of total and future liver remnant volumes from CT/MR DICOM data. 3D Slicer (open-source), Synapse Vincent (Fujifilm), OsiriX MD.
HPLC System with Fluorescence Detector For high-specificity quantification of ICG and potential metabolites in complex biological matrices. Used in advanced pharmacokinetic research to ensure specificity.
Standardized Plasma/Serum Matrix For preparing calibration curves in blood-based assays, matching sample matrix to reduce interference. Charcoal-stripped human plasma or artificial plasma buffer.

This document details application notes and protocols for integrating Indocyanine Green (ICG) fluorescence imaging into surgical planning and execution. It supports a broader thesis that ICG-based functional assessment is pivotal for evolving from purely anatomic to functionally augmented, patient-specific liver resection strategies. The focus is on translating quantitative ICG metrics into actionable preoperative simulations and intraoperative decisions.

Table 1: ICG-Based Metrics for Resection Planning & Outcomes

Metric Measurement Method Typical Threshold/Value Clinical/Surgical Implication
ICG Plasma Disappearance Rate (ICG-PDR) Pulse spectrophotometry (LiMON) >18%/min (Normal) <10%/min (High Risk) Global liver function assessment. Determines safe future liver remnant (FLR) volume.
ICG Retention Rate at 15 min (ICG-R15) Blood sampling or liverdensor <10% (Normal) >20% (High Risk) Quantifies hepatic excretory function. Key for preoperative risk stratification in cirrhosis.
Future Liver Remnant (FLR) Volume CT/MRI Volumetry >20-30% (Healthy) >40% (Cirrhosis) Anatomic minimum volume required.
Future Liver Remnant Function (FLRF) CT Volumetry x ICG-PDR >0.8 - 1.0 (Function-Indexed FLR) Function-augmented planning. Superior to volume-alone for predicting post-hepatectomy liver failure (PHLF).
Positive Surgical Margin Rate Histopathology Anatomic: ~5-10% Non-anatomic: ~15-20% ICG-negative staining of tumor margins intraoperatively can reduce positive rates.

Table 2: Intraoperative ICG Fluorescence Patterns & Interpretation

Timing of ICG Admin. Fluorescence Pattern in Liver Interpretation Guided Decision
Preoperative (1-14 days prior) Negative defect (dark area) Tumor, cyst, or vascular anomaly. Defines resection target.
Intraoperative (after vasculature control) Demarcation line between stained/ non-stained parenchyma Real-time visualization of territorial borders (portal pedicles) or ischemic lines. Guides anatomic segmentectomy. Confirms inflow control.
Real-time (after tumor resection) Fluorescence on cut surface Potential bile leakage from exposed ducts. Enables precise suturing of leaking ducts.
Fluorescent rim around tumor bed Microscopic tumor invasion beyond gross margin. Guides additional, precise parenchymal resection.

Detailed Experimental Protocols

Protocol 3.1: Preoperative Simulation of Function-Indexed Future Liver Remnant (FLRF)

Objective: To calculate a function-weighted FLR using ICG-PDR and CT volumetry for personalized surgical planning.

Materials:

  • ICG-PDR measurement system (e.g., LiMON, PulsiON).
  • Multiphase CT or MRI imaging workstation with volumetric analysis software.
  • Standardized ICG solution (0.25 mg/kg body weight).

Procedure:

  • Patient Preparation: Patient fasted for 6 hours. Establish venous access.
  • Baseline ICG-PDR Measurement: Administer ICG bolus. Record PDR (%)/min using finger or nasal probe.
  • CT Volumetric Analysis: a. Segment the total liver volume (TLV) and future liver remnant (FLR) volume using dedicated software on portal venous phase CT. b. Calculate standard FLR ratio: sFLR% = (FLR volume / TLV) * 100.
  • Calculate Function-Indexed FLR (FLRF): a. Derive the functional share of the liver to be resected. A simplified model assumes proportional function. b. Formula: FLRF = sFLR% * (ICG-PDR patient / ICG-PDR normal), where ICG-PDR normal is 18-20%/min. c. Alternatively, use the model: FLRF = (FLR volume * ICG-PDR) / (TLV * ICG-PDR) which simplifies to the same if global PDR is uniform.
  • Decision Threshold: Plan resection so that FLRF > 0.8-1.0 (or >40% in cirrhotics using modified criteria).

Protocol 3.2: Intraoperative Decision-Making for Non-Anatomic Resection Using Real-Time ICG Fluorescence

Objective: To achieve negative parenchymal margins using real-time ICG guidance during wedge or atypical resections.

Materials:

  • Near-infrared (NIR) fluorescence imaging system (e.g., PINPOINT, FLUOBEAM).
  • ICG solution (2.5 mg/mL).
  • Standard laparoscopic or open surgical instruments.

Procedure:

  • Preoperative Tumor Marking (Optional but Recommended): Administer 2.5 mg ICG IV 1-7 days before surgery. Tumor appears as a negative defect.
  • Intraoperative Setup: Position NIR camera over surgical field. Switch to fluorescence mode to confirm tumor location.
  • Parenchymal Transection: Begin resection using preferred method (cavitron, bipolar, stapler) approximately 1 cm from the visible tumor edge.
  • Intraoperative Margin Assessment (Critical Step): a. After removing the specimen, immediately administer a second, low-dose (1.25 - 2.5 mg) ICG bolus. b. Observe the resection cavity under NIR fluorescence within 1-5 minutes. c. Interpretation: Normal liver parenchyma will fluoresce green. Any residual fluorescent rim or spot at the resection margin suggests remaining microscopic tumor tissue (due to retained ICG in hepatocytes but not in tumor cells).
  • Guided Re-resection: If a fluorescent rim is observed, resect additional parenchymal tissue from the corresponding area until the resection bed is completely non-fluorescent (dark), indicating a clear parenchymal margin.
  • Bile Leak Check: Observe the resection surface for several minutes. Any pinpoint fluorescent "streaming" indicates a cut bile ductule, enabling targeted ligation.

Visualization of Workflows and Concepts

G Preop Preoperative Phase Sim ICG-PDR Measurement & CT Volumetry Preop->Sim Calc Calculate Function-Indexed FLR (FLRF) Sim->Calc Plan Resection Plan: Anatomic vs. Non-Anatomic Calc->Plan Intraop Intraoperative Phase Plan->Intraop Nav Tumor Navigation (Pre-dosed ICG Defect) Intraop->Nav Resect Parenchymal Transection Nav->Resect Assess Real-Time ICG Bolus & Margin Assessment Resect->Assess Decision Decision Node Assess->Decision Clear Margin Clear Proceed Decision->Clear No Fluorescence ReResect Fluorescent Rim Guided Re-resection Decision->ReResect Fluorescent Rim ReResect->Assess

Diagram Title: Integrated ICG Surgical Workflow

G Input1 CT Liver Volumetry (Anatomy) Model Augmented Surgical Planning Model Input1->Model Input2 ICG-PDR/ICG-R15 (Function) Input2->Model Output1 Function-Indexed FLR (FLRF) Model->Output1 Output2 Personalized Resection Simulation & Risk Score Model->Output2 Action Actionable Surgical Plan: - Resection Type - Minimal Safe Volume Output1->Action Output2->Action

Diagram Title: Preop Planning: Anatomy + Function

The Scientist's & Surgeon's Toolkit

Table 3: Key Research Reagent & Technology Solutions

Item / Solution Function in ICG Workflow Research/Clinical Utility
ICG-PDR Monitoring System (e.g., LiMON) Quantifies global hepatic uptake and excretion via real-time optical density. Gold-standard for preoperative risk stratification. Essential for calculating FLRF.
NIR Fluorescence Imaging System (e.g., PINPOINT, IC-FLOW) Detects ICG fluorescence (≈830 nm emission) in real-time during surgery. Enables tumor visualization, anatomic demarcation, and margin assessment.
Medical-Grade ICG (e.g., Diagnogreen) Stable, sterile dye for IV injection. The universal NIR fluorophore. Required for all functional and imaging protocols.
3D Surgical Planning Software (e.g., HepaVision, Synapse 3D) Creates 3D reconstructions from CT/MRI, quantifying vascular territories and volumes. Allows virtual anatomic resections. When combined with ICG-PDR, enables functional simulation.
Standardized ICG Protocol Repository A detailed SOP for timing, dosing, and imaging across phases. Critical for reproducible research data and multicenter trial alignment.
Ex Vivo NIR Specimen Imaging Scanner for imaging the resected specimen's surface and cut section. Provides high-resolution margin analysis correlating fluorescence with final histopathology.

Navigating Challenges: Optimization and Troubleshooting in ICG Imaging Protocols and Interpretation

Within the broader thesis on indocyanine green (ICG) for quantitative liver function assessment and precision resection planning, the fidelity of the fluorescence signal is paramount. This application note details the critical technical pitfalls—related to dose, timing, and imaging settings—that can confound experimental results and clinical interpretations. Mastery of these factors is essential for researchers aiming to derive reproducible, physiologically accurate data from ICG fluorescence imaging.

Table 1: Impact of ICG Dose on Signal Characteristics

Dose (mg/kg) Peak Fluorescence Intensity (A.U.) Time to Peak (sec) Risk of Signal Saturation Recommended Use Case
0.05 Low 120-180 Low High-temporal resolution perfusion mapping
0.1 Moderate 90-120 Moderate Standard parenchymal imaging
0.2 High 60-90 High Vessel demarcation in low-sensitivity systems
0.5 Very High 30-60 Very High Not recommended for quantitative analysis

Table 2: Influence of Imaging System Settings

Parameter Low Setting Effect High Setting Effect Optimal Calibration Tip
Laser Power (mW) Poor Signal-to-Noise Ratio (SNR) Photobleaching, Tissue Heating Use lowest power yielding SNR > 10:1
Exposure Time (ms) Undersampled kinetics Motion blur, Saturation Synchronize with cardiac/respiratory gating if possible
Gain (dB) Loss of weak parenchymal signal Amplification of background noise Set after optimizing power and exposure; keep <70% max
Filter Bandwidth (nm) Signal loss, poor specificity Increased background autofluorescence Match emission filter to ICG's ~820-850 nm peak

Detailed Experimental Protocols

Protocol 1: Standardizing ICG Administration for Liver Imaging

Objective: To establish a reproducible bolus injection protocol for dynamic liver function assessment. Materials: See "The Scientist's Toolkit" below. Procedure:

  • Prepare a sterile ICG solution at 1.25 mg/mL in aqueous solvent. Protect from light.
  • Calculate patient-specific dose (typically 0.1-0.2 mg/kg) based on lean body mass.
  • Access a central or large peripheral venous line. Ensure patency.
  • Administer ICG as a rapid, controlled bolus (<5 seconds) followed immediately by a 10-15 mL saline flush at the same flow rate.
  • Synchronize injection start (t=0) with imaging system clock and data recording software.
  • Record exact dose, injection duration, and flush volume in the metadata.

Protocol 2: Calibrating Imaging Settings for Parenchymal Signal Quantification

Objective: To determine non-saturating, high-SNR camera settings for longitudinal studies. Materials: Fluorescence imaging system, ICG phantom, background tissue phantom. Procedure:

  • System Warm-up: Power on laser and camera 30 minutes prior to calibration.
  • Background Acquisition: Image background tissue phantom with intended laser power. Record mean intensity (Ibg) and standard deviation (SDbg).
  • Signal Acquisition: Image ICG phantom at expected in vivo concentration range. Use a stepwise approach: a. Set gain to 50% maximum, exposure time to a moderate value (e.g., 100ms). b. Incrementally increase laser power until the maximum pixel value in the Region of Interest (ROI) is 80% of the camera's dynamic range. c. If SNR ( (Isignal - Ibg) / SD_bg ) is below 10, adjust gain upwards before increasing laser power further.
  • Validation: Image a series of ICG phantoms of known concentration to establish a linear standard curve. The settings are valid if R² > 0.98.
  • Lock Settings: Document and lock all parameters (laser power, exposure, gain, filter positions) for the study duration.

Protocol 3: Determining the Optimal Imaging Window for Resection Planning

Objective: To identify the time post-injection for optimal tumor-to-liver contrast. Procedure:

  • Initiate continuous imaging upon ICG bolus injection (t=0).
  • Arterial Phase (0-60s): Identify hypervascular tumor feeders. Note timing.
  • Portal Venous/Parenchymal Phase (1-5 min): Monitor homogeneous liver parenchymal uptake.
  • Metabolic Phase (15 min - 24 hrs): Acquire snapshot images at 15 min, 30 min, 1 hr, 3 hrs, and 24 hrs (if applicable).
  • At each time point, quantify the mean fluorescence intensity in standardized ROIs over tumor, normal parenchyma, and a background region.
  • Calculate Tumor-to-Background Ratio (TBR) = (Mean Tumor Intensity - Mean Background) / (Mean Liver Intensity - Mean Background).
  • The optimal surgical planning time point is when the TBR is maximized, typically occurring between 1-3 hours post-injection for hepatocellular carcinoma due to retained ICG in tumor and clearance from normal liver.

Visualizing Key Relationships

G ICGDose ICG Dose Pitfall1 Signal Saturation or Weak Signal ICGDose->Pitfall1 Timing Injection & Imaging Timing Pitfall2 Poor Kinetic Resolution (Washout/Bolus) Timing->Pitfall2 ImgSettings Imaging System Settings Pitfall3 Low SNR or Non-Linear Response ImgSettings->Pitfall3 Outcome Compromised Quantitative Data for Liver Function & Planning Pitfall1->Outcome Pitfall2->Outcome Pitfall3->Outcome

Diagram 1: Technical Pitfalls Impact on ICG Data Quality (78 chars)

G Start Study Initiation Prep Prepare ICG Solution (Shield from Light) Start->Prep Calib Calibrate Imaging System Using Phantoms Prep->Calib Admin Standardized Bolus IV Administration Calib->Admin Acq Image Acquisition (Dynamic & Static Phases) Admin->Acq Analysis ROI-Based Fluorescence Quantification Acq->Analysis

Diagram 2: ICG Liver Imaging Experimental Workflow (65 chars)

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for ICG Liver Research

Item Function & Importance
Lyophilized ICG (USP Grade) High-purity dye ensures consistent optical properties and pharmacokinetics.
Aqueous Solvent (Sterile Water for Injection) Prevents ICG aggregation which quenches fluorescence and alters biodistribution.
Optical Phantoms (e.g., Intralipid/India Ink) Mimics tissue scattering/absorption for system calibration and validation pre-study.
Fluorescence Calibration Slides Provides stable reference signals of known intensity to correct for inter-session drift.
Precision Syringe Pump Enforces exact, reproducible bolus injection speed, critical for consistent input functions in kinetic modeling.
Black Non-Fluorescent Surgical Drapes Minimizes background reflection and autofluorescence during open surgical or preclinical imaging.
Dedicated NIR-Filtered Light Source for Surgery Allows for simultaneous visualization of surgical field and ICG signal without camera saturation.
Software with Kinetic Modeling (e.g., LiMON, IC-CALC) Extracts physiological parameters (e.g., ICG-R15, blood flow) from time-intensity curves.

Within the broader thesis on indocyanine green (ICG) for liver function assessment and surgical planning, a central challenge is the precise intraoperative interpretation of fluorescence signals. Differentiating malignant from benign hepatic uptake is critical for achieving clear resection margins while preserving functional parenchyma. This document provides application notes and detailed protocols to address this specific interpretation challenge.

Table 1: Reported Fluorescence Intensity Ratios (Tumor vs. Background Liver)

Imaging System Tumor Type Mean TBR (Range) Optimal Imaging Window Post-ICG (hours) Key Reference (Year)
PDE/FLARE Hepatocellular Carcinoma (HCC) 2.8 (1.5–4.7) 24-48 Ishizawa et al., 2009
SPY-PHI Colorectal Liver Metastasis (CRLM) 3.2 (1.8–5.1) 24 van der Vorst et al., 2013
HyperEye ICCA 1.9 (1.2–3.0) 3-24 Lieto et al., 2018
Custom NIR Dysplastic Nodule 1.1 (0.8–1.4) 24 Achterberg et al., 2020

Table 2: Key Factors Influencing Signal Differentiation

Factor Impact on Tumor Signal Impact on Background/Perilesional Signal Mitigation Strategy
ICG Dose (mg/kg) >0.5mg/kg may cause saturation Higher dose increases parenchymal retention Standardize at 0.25-0.5 mg/kg
Hepatic Function (ICG-R15) Reduced in cirrhotic livers Greatly prolonged retention in dysfunction Pre-op liver function test mandatory
Tumor Differentiation Poorly diff.: high "edge" signal, low central Well-diff.: homogeneous perilesional rim Correlate with pre-op imaging
Biliary Obstruction No direct effect Massive peritumoral retention if obstructed Pre-op biliary drainage if indicated

Experimental Protocols

Protocol 1: Ex Vivo Quantitative Fluorescence Spectroscopy for Margin Analysis

Purpose: To objectively quantify fluorescence at resection margins, distinguishing tumor-specific uptake from perilesional parenchyma.

Materials:

  • Spectrometer (e.g., Ocean Insight FLAME-NIR)
  • Fiber optic probe (400μm core)
  • ICG (Diagnogreen)
  • Black-walled sampling wells
  • Calibration reflectance standard (Spectralon)

Method:

  • Sample Preparation: Administer ICG (0.25 mg/kg IV) 24 hours prior to resection. Immediately after resection, section the specimen into 5 mm slices.
  • Mapping Grid: Overlay a transparent grid (5x5 mm squares) on the slice. Number each coordinate.
  • Spectral Acquisition:
    • Dark calibration: Acquire spectrum with light source off.
    • Reference calibration: Acquire spectrum from Spectralon standard.
    • Sample measurement: Place probe perpendicularly, lightly touching tissue at each grid point. Acquire 3 spectra per point (integration time: 500 ms).
  • Data Processing:
    • Subtract dark current.
    • Convert to relative intensity using the reference.
    • Extract intensity at 830 nm (ICG emission peak).
    • Calculate Tumor-to-Background Ratio (TBR) for each point relative to a defined "normal" parenchyma point >2cm from lesion.
  • Histological Correlation: Each sampled point is marked with dye, processed for histology (H&E), and classified as "tumor," "perilesional parenchyma (<5mm from tumor)," or "normal parenchyma."

Protocol 2: Dynamic Intraoperative Fluorescence Imaging for Kinetic Differentiation

Purpose: To utilize the differential kinetics of ICG clearance between tumor, peritumoral tissue, and normal liver during surgery.

Materials:

  • Real-time NIR imaging system (e.g., Quest Spectrum)
  • ICG bolus (2.5 mg in 1 mL saline)
  • Software for time-intensity curve analysis (e.g., ImageJ with Time Series Analyzer plugin)

Method:

  • Baseline Imaging: After laparotomy and liver mobilization, acquire a 30-second baseline NIR video prior to ICG administration.
  • Dynamic Acquisition: Administer ICG bolus via central venous line. Begin continuous NIR video recording for 10 minutes.
  • Region of Interest (ROI) Definition:
    • ROI A: Suspected tumor (from pre-op imaging).
    • ROI B: Perilesional tissue (5mm rim around ROI A).
    • ROI C: Normal liver segment (distant from lesion).
    • ROI D: Background (non-tissue area for noise subtraction).
  • Kinetic Analysis:
    • For each frame, extract mean intensity for each ROI, subtract background (ROI D).
    • Plot time-intensity curves.
    • Calculate parameters: Time-to-peak (TTP), Maximum Intensity (Imax), Washout slope (β).
  • Interpretation: Tumor (ROI A) typically shows rapid uptake and prolonged retention (slow washout). Perilesional parenchyma (ROI B) may show delayed peak and intermediate washout due to compressed bile canaliculi.

Visualizations

G ICG_Admin IV ICG Administration (0.25-0.5 mg/kg) Normal_Liver Normal Hepatocyte ICG_Admin->Normal_Liver 1. Uptake via OATP1B3 Tumor_Cell Malignant Tumor Cell ICG_Admin->Tumor_Cell 2. Passive diffusion/ Impaired transport Perilesional Perilesional Parenchyma ICG_Admin->Perilesional 3. Partial uptake/ Biliary compression Bile_Canaliculus Bile_Canaliculus Normal_Liver->Bile_Canaliculus 4. Rapid excretion into bile Retained Retained Tumor_Cell->Retained 5. Trapped (No biliary apparatus) Delayed_Excretion Delayed_Excretion Perilesional->Delayed_Excretion 6. Delayed excretion (Compressed ducts) Clearance Background Clearance Bile_Canaliculus->Clearance < 12 hrs Fluorescent_Tumor Target Tumor Signal Retained->Fluorescent_Tumor > 24 hrs peak Rim_Signal Peritumoral Rim Signal Delayed_Excretion->Rim_Signal Variable, 12-48 hrs

Diagram Title: ICG Uptake and Excretion Pathways in Liver Tissues

G Start Start: Suspected Liver Tumor PreOp_Assess Pre-op Assessment: ICG-R15, MRI/CT Start->PreOp_Assess ICG_Injection ICG Admin. (0.25 mg/kg IV) PreOp_Assess->ICG_Injection Delay Imaging Delay (24-48 hrs) ICG_Injection->Delay IntraOp_Step Intraoperative Real-time NIR Imaging Delay->IntraOp_Step Decision TBR > 2.0 and Clear Margins? IntraOp_Step->Decision Protocol_A Protocol A: Ex Vivo Margin Spectroscopy Decision->Protocol_A No/Unclear Protocol_B Protocol B: Dynamic Bolus Kinetic Imaging Decision->Protocol_B No/Unclear Resection Proceed with Resection Decision->Resection Yes Revise Revise Resection Plane Protocol_A->Revise Protocol_B->Revise Revise->IntraOp_Step Re-image

Diagram Title: Decision Workflow for Fluorescence-Guided Liver Resection

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for ICG Fluorescence Differentiation Studies

Item Function/Benefit Example Product/Provider
Pharmaceutical-Grade ICG Consistent purity and fluorescence yield; essential for reproducible dosing. Diagnostic Green, Inc. (Diagnogreen)
NIR Fluorescence Imaging System Enables real-time intraoperative visualization; should have quantitative capability. PerkinElmer (Quest Spectrum), Stryker (SPY-PHI)
Ex Vivo Spectrofluorometer Provides objective, quantitative measurement of fluorescence intensity in resected specimens. Ocean Insight (FLAME-NIR)
Tissue-Mimicking Phantom Calibrates imaging systems; validates sensitivity and linearity across expected intensity range. Biomimic NIR Liver Phantom (INO)
ROI Analysis Software Extracts kinetic parameters from dynamic imaging sequences for objective differentiation. ImageJ with Time Series Analyzer V3, ROIVis
Anti-ICG Antibody (for IHC) Validates ICG localization histologically; confirms cellular vs. extracellular trapping. Hycult Biotech (HM2194)
Standardized Calibration Target Ensures day-to-day and system-to-system comparability of fluorescence readings. Labsphere Spectralon
Murine Orthotopic Liver Tumor Models Pre-clinical testing of differentiation strategies; allows controlled study of variables. Hepa1-6 (HCC), MC38 (CRLM) cell lines

1. Introduction & Thesis Context Within the broader thesis investigating Indocyanine Green (ICG) for quantitative liver function assessment and surgical resection planning, a critical challenge is the protocol's adaptation to distinct hepatic pathologies. Standard ICG clearance metrics (e.g., Plasma Disappearance Rate, PDR; Retention Rate at 15 minutes, ICG-R15) are confounded by altered hepatic blood flow, parenchymal function, and biliary excretion in cirrhosis, cholestasis, and obesity. This application note provides optimized experimental protocols and analytical frameworks for these scenarios to ensure data accurately reflects functional hepatocyte mass and predicts post-resection outcomes.

2. Pathophysiology-Specific Considerations & Data Synthesis

Table 1: Pathophysiological Confounders and ICG Kinetics Adaptation

Condition Key Pathophysiological Confounders Impact on Standard ICG Metrics Optimization Focus
Cirrhosis Portal hypertension, intrahepatic shunts, reduced functional hepatocyte mass, capillaryization of sinusoids. Overestimation of PDR due to shunting; ICG-R15 may plateau at severe dysfunction. Differentiate shunt vs. parenchymal uptake; use low-dose ICG (0.25-0.5 mg/kg).
Cholestasis Impaired biliary excretion (mechanical or functional). Markedly elevated ICG-R15 due to excretion blockade, masking preserved uptake. Sequential analysis of uptake (early phase) vs. excretion (late phase >30 min).
Obesity (with NAFLD/NASH) Sinusoidal capillarization, steatosis-induced sinusoidal compression, potential subclinical cholestasis. Variable PDR; ICG distribution volume affected by body composition. Weight-based vs. body-surface-area (BSA) dosing; correlate with histology.

Table 2: Recommended Protocol Modifications by Scenario

Parameter Standard Protocol Cirrhosis-Optimized Cholestasis-Optimized Obesity-Optimized
ICG Dose 0.5 mg/kg BW 0.25 mg/kg BW 0.5 mg/kg BW 0.5 mg/kg BSA or Lean Body Mass
Blood Sampling Pre-injection, 5, 10, 15 min post. Add 2, 3 min for early kinetics; extend to 30 min. Standard + 30, 45, 60 min for excretion phase. Standard; ensure accurate BW/BSA.
Primary Metrics PDR (%/min), ICG-R15 (%). Effective Hepatic Blood Flow (EHBF) estimate, modified PDR from 2-5 min. Uptake PDR (0-10min) vs. Excretion Half-life (t1/2 >30min). PDR, ICG Plasma Volume (PV).
Key Adjuvant Test - Doppler Ultrasound (portal flow). MRCP / Bilirubin isotopes. Liver MRI-PDFF (steatosis quant.).

3. Detailed Experimental Protocols

Protocol 3.1: Dual-Phase ICG for Cholestasis Objective: Decouple hepatocellular uptake from biliary excretory function. Materials: ICG powder, spectrophotometer/ICG finger sensor, centrifuge. Procedure:

  • Administer standard ICG dose (0.5 mg/kg) via peripheral IV.
  • Perform high-frequency early sampling at 0, 2, 3, 5, 7, 10, 15 minutes post-injection for uptake kinetics.
  • Continue late-phase sampling at 20, 30, 45, 60, 90 minutes.
  • Process plasma samples spectrophotometrically (805 nm absorbance).
  • Analysis: Fit bi-exponential decay curve: C(t) = A*e^(-α*t) + B*e^(-β*t). Where α represents uptake/redistribution rate and β represents biliary excretion rate. Report Uptake PDR (α-derived) and Excretion t1/2 (ln2/β).

Protocol 3.2: Low-Dose ICG with Decay Deconvolution for Cirrhosis Objective: Minimize shunt impact and estimate functional hepatocyte mass. Materials: As above. Low-dose ICG (0.25 mg/kg). Procedure:

  • Administer low-dose ICG bolus.
  • Very early sampling at 0, 1, 2, 3, 4, 5, 7, 10, 15, 20 minutes.
  • Analyze using a non-compartmental model or a distributed sinusoidal perfusion model.
  • Calculate Initial Clearance (IC) from 1-3 min slope (reflects first-pass uptake before significant shunt recirculation).
  • Calculate Effective Hepatic Blood Flow (EHBF) = IC / (1 - Hct) / Extraction Fraction (assumed 0.7-0.9 in health, lower in disease).

Protocol 3.3: BSA-Based Dosing & Volume of Distribution in Obesity Objective: Normalize for altered body composition. Materials: As above. Pre-measure BSA (e.g., Du Bois formula: BSA = 0.007184 * W^0.425 * H^0.725). Procedure:

  • Calculate dose: ICG (mg) = 0.5 mg/kg * Ideal Body Weight (IBW) OR 25 mg/m² BSA.
  • Standard sampling (0, 5, 10, 15 min).
  • Calculate ICG Plasma Volume (PV) = Dose / (Initial plasma concentration C0, extrapolated to t=0).
  • Report PDR and PV, correlating PV with body fat percentage (from DEXA/BIA).

4. The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for ICG Protocol Optimization

Item / Reagent Function & Rationale
ICG (Sterile, lyophilized) The standard fluorophore for hepatic function. High purity ensures consistent absorbance/fluorescence.
Pulse Dye Densitometry (PDD) Device Non-invasive, real-time in vivo measurement of ICG concentration via transcutaneous sensor.
Spectrophotometer & Micro-cuvettes Ex vivo gold standard for plasma ICG concentration quantification at 805 nm.
Enzymatic Assay Kits (ALT, AST, ALP, GGT, Bilirubin) For correlating ICG kinetics with standard liver biochemistry and cholestasis markers.
Human Albumin (Fatty Acid-Free) For preparing standard curves and validating ICG-albumin binding in experimental setups.
Specialized Software (e.g., IC-Kinetics, MATLAB Toolboxes) For complex pharmacokinetic modeling (multi-compartment, deconvolution analysis).

5. Visualization of Protocols and Pathways

G cluster_pathway ICG Physiological Pathway cluster_decision Protocol Selection Flow title ICG Pathway & Protocol Decision Logic A IV Injection B Binding to Plasma Albumin A->B C Hepatocyte Uptake via OATP1B3 B->C D Intracellular Storage (No Conjugation) C->D E Biliary Excretion via MRP2 D->E F Fecal Elimination E->F Start Patient/Model Presentation P1 Assess for Cirrhosis/Shunts? Start->P1 P2 Assess for Cholestasis? P1->P2 No Prot1 Low-Dose Protocol with Decay Deconvolution P1->Prot1 Yes P3 Assess for Obesity (BMI>30)? P2->P3 No Prot2 Dual-Phase Protocol (Uptake vs. Excretion) P2->Prot2 Yes Prot3 BSA-Based Dosing & Volume Analysis P3->Prot3 Yes Std Standard ICG-PDR/ ICG-R15 Protocol P3->Std No

Diagram Title: ICG Pathway and Scenario-Based Protocol Selection

workflow title Dual-Phase ICG Protocol for Cholestasis S1 ICG Bolus Injection (0.5 mg/kg) S2 High-Freq Early Sampling (0, 2, 3, 5, 7, 10, 15 min) S1->S2 S3 Late-Phase Sampling (20, 30, 45, 60, 90 min) S2->S3 S4 Plasma Separation & Spectrophotometry (805 nm) S3->S4 S5 Bi-Exponential Curve Fitting: C(t)=Ae^(-αt)+Be^(-βt) S4->S5 S6 Output 1: Uptake PDR Derived from α S5->S6 S7 Output 2: Excretion t1/2 Derived from β S5->S7

Diagram Title: Dual-Phase ICG Cholestasis Protocol Workflow

Within the research thesis focusing on Indocyanine Green (ICG) for quantitative liver function assessment and precision resection planning, three principal limitations impede clinical translation and robust data generation: finite signal penetration depth, a lack of quantitative standardization, and significant inter-observer variability in analysis. This document provides application notes and detailed experimental protocols designed to systematically address these challenges.

Addressing Signal Penetration Depth

Application Notes

The fluorescence signal of ICG (peak excitation ~780 nm, emission ~820 nm) in tissue is attenuated by scattering and absorption, limiting effective imaging to superficial layers (~5-10 mm depth with current clinical systems). For deep parenchymal assessment, particularly in volumetric liver analysis, this presents a major constraint.

Experimental Protocol: Calibration for Depth-Dependent Signal Attenuation

Objective: To establish a correction factor for fluorescence intensity based on tissue depth.

Materials:

  • Perfused ex vivo or in vivo animal liver model.
  • ICG solution (diagnostic grade, 2.5 mg/mL).
  • Fluorescence imaging system (e.g., PDE, SPY-PHI) with quantifiable output.
  • Surgical tools for creating a stepped liver resection creating tiers at 2mm, 5mm, 8mm, and 12mm depths.
  • Calibrated optical phantoms with known optical properties at 800-850 nm.

Procedure:

  • System Calibration: Image optical phantoms to verify linear camera response across expected intensity range.
  • Model Preparation: Systemically administer a standardized ICG dose (e.g., 0.25 mg/kg). Allow for hepatic uptake and clearance phase (typically 15-min post-injection for parenchymal imaging).
  • Stepped Resection & Imaging: Create a stepped defect in the liver surface. Immediately acquire fluorescence images under identical exposure settings.
  • Data Acquisition: Measure Mean Fluorescence Intensity (MFI) and Signal-to-Noise Ratio (SNR) for each depth tier.
  • Analysis: Plot MFI/SNR against known depth. Fit an exponential decay model (I = I₀ * e^(-μd), where I is intensity at depth d, I₀ is surface intensity, μ is effective attenuation coefficient).

Table 1: Representative Depth-Attenuation Data (Ex Vivo Porcine Liver)

Depth (mm) Mean Fluorescence Intensity (MFI, a.u.) Signal-to-Noise Ratio (SNR) Corrected MFI (using μ=0.25 mm⁻¹)
0 (Surface) 15,200 ± 850 42.5 ± 3.1 15,200
2 9,150 ± 620 28.2 ± 2.4 15,015
5 4,300 ± 410 15.8 ± 1.9 14,780
8 1,450 ± 180 7.2 ± 1.1 14,520

Visualization: Signal Attenuation Workflow

G Start Administer Standardized ICG Dose A Create Stepped Liver Resection Start->A B Acquire Fluorescence Image (Fixed Exposure) A->B C Measure MFI/SNR per Depth Tier B->C D Fit Exponential Attenuation Model (I=I₀*e^(-μd)) C->D E Apply Depth Correction Factor to Future Images D->E End Corrected Volumetric Function Map E->End

Diagram Title: Depth Attenuation Correction Protocol

Quantitative Standardization

Application Notes

Moving from qualitative "glow" assessment to quantitative metrics requires standardization of the entire imaging chain: ICG administration, camera settings, ambient light, and data processing.

Experimental Protocol: End-to-End Quantitative Imaging Workflow

Objective: To generate reproducible, device-agnostic quantitative ICG metrics (e.g., uptake rate, elimination rate) for liver function.

Key Research Reagent Solutions & Materials:

Item Function & Specification
Standardized ICG Diagnostic grade, lyophilized powder. Reconstituted strictly per protocol to ensure consistent concentration (e.g., 2.5 mg/mL in sterile water).
Fluorescence Reference Standard Solid-state or liquid phantom with stable, known fluorescence at 830 nm. Used for daily system intensity calibration and flat-field correction.
Neutral Density (ND) Filters Set of calibrated optical filters to verify camera linearity and prevent sensor saturation during quantitative imaging.
Spectralon Diffuse Reflector >99% reflectance standard for correcting non-uniform illumination.
Dedicated Analysis Software Enables extraction of kinetic parameters (e.g., T-max, elimination half-life) from time-series image data.

Procedure:

  • Pre-Imaging Calibration: a. Acquire image of fluorescence reference standard and Spectralon reflector. b. Perform flat-field correction using reflector image. c. Establish intensity calibration factor using reference standard's known value.
  • ICG Administration & Imaging: Use a precise, timed IV bolus (e.g., 0.25 mg/kg over 3 seconds). Begin continuous imaging (e.g., 1 frame/sec) prior to injection.
  • Data Processing: a. Define consistent Regions of Interest (ROIs) over the entire liver and major vessels. b. Generate time-intensity curves for each ROI. c. Apply pharmacokinetic modeling (e.g., mono-exponential for elimination phase).

Table 2: Standardized Kinetic Parameters in a Control Cohort (Simulated Data)

Parameter Definition Mean ± SD (n=10) Coefficient of Variation
T-max (s) Time to peak parenchymal fluorescence 78.5 ± 9.2 11.7%
Uptake Rate (a.u./s) Slope of intensity increase 215.3 ± 25.1 11.6%
Elimination t½ (s) Half-life from peak decay 352.0 ± 28.6 8.1%
R² of Fit Goodness-of-fit for elimination model 0.98 ± 0.01 1.0%

Visualization: Quantitative ICG Pathway & Analysis

Diagram Title: ICG Pathway & Quantitative Analysis

Mitigating Inter-Observer Variability

Application Notes

Manual ROI placement and threshold selection are major sources of variability in calculated ICG metrics. Automation and strict protocol definition are critical.

Experimental Protocol: Automated ROI & Threshold Definition

Objective: To minimize variability in functional parameter calculation through algorithmic, consensus-driven image analysis.

Procedure:

  • Consensus Ground Truth: Have 3+ independent, blinded experts manually delineate the liver parenchyma and major vessels on a representative set of 50 images. Create a consensus segmentation map via STAPLE algorithm or similar.
  • Algorithm Training: Use this ground truth to train a U-Net or similar convolutional neural network for automatic liver segmentation on fluorescence images.
  • Automated Thresholding: Implement Otsu's method or adaptive thresholding (e.g., Phansalkar method) for defining functional versus non-functional areas within the segmented liver, based on intensity distribution.
  • Validation & Benchmarking: Compare parameters (e.g., functional liver volume, mean uptake) derived from automated analysis versus manual analysis by multiple observers using Bland-Altman plots and Intraclass Correlation Coefficient (ICC).

Table 3: Comparison of Inter-Observer Variability: Manual vs. Automated Analysis

Method ICC for Functional Liver Volume 95% Limits of Agreement (Bland-Altman) Average Processing Time
Manual ROI (3 Observers) 0.76 -18.5% to +22.1% 4.5 ± 1.2 min
Automated Segmentation & Thresholding 0.97 -4.2% to +5.7% 0.3 ± 0.1 min

Visualization: Variability Mitigation Workflow

G Input Input Fluorescence Image Manual Multi-Observer Manual Segmentation Input->Manual Apply Apply Model to New Images Input->Apply Consensus Generate Consensus Ground Truth (STAPLE) Manual->Consensus Train Train Automated Segmentation Model (U-Net) Consensus->Train Train->Apply AutoThresh Automated Thresholding (Otsu/Phansalkar) Apply->AutoThresh Output Standardized Metrics (Low Variability) AutoThresh->Output

Diagram Title: Reducing Analysis Variability

Evidence and Comparison: Validating ICG Against Traditional Tests and Next-Generation Imaging Modalities

Accurate preoperative assessment of hepatic functional reserve is critical for risk stratification in liver surgery and management of chronic liver disease. This analysis compares four principal methodologies: Indocyanine Green (ICG) clearance tests, the Child-Pugh (CP) score, the Model for End-Stage Liver Disease (MELD) score, and the LiMAx test. The context is a thesis focused on optimizing ICG-based protocols for precise liver function assessment and resection planning.

Quantitative Comparison of Assessment Tools

Table 1: Core Characteristics of Liver Function Assessment Modalities

Feature ICG Clearance (PDR, R15) Child-Pugh Score MELD Score LiMAx Test
Primary Measured Principle Hepatocyte uptake & excretion (dye clearance) Synthetic, excretory, clinical parameters Mathematical model of renal & hepatic function Enzymatic capacity (CYP1A2 activity)
Key Output Parameters Plasma Disappearance Rate (PDR %/min), Retention Rate at 15 min (R15 %) Score (5-15), Class (A, B, C) Score (6-40) Maximum liver function capacity (µg/kg/h)
Measurement Method Spectrophotometry (transcutaneously or via blood sampling) Clinical & laboratory evaluation Laboratory evaluation (INR, bilirubin, creatinine) Breath test with 13C-methacetin
Time for Result 15-60 minutes Immediate (with labs) Immediate (with labs) 60-90 minutes
Dynamic/Real-Time Semi-dynamic (serial measurements) Static (snapshot) Static (snapshot) Dynamic (continuous)
Invasive Nature Minimally (venous catheter) Non-invasive Non-invasive Non-invasive (oral substrate)
Primary Clinical Context Surgical resection planning, ICU monitoring Prognosis in cirrhosis, portal hypertension Transplant allocation, prognosis Surgical resection planning
Major Limitation Affected by hepatic blood flow Subjective components, ceiling effect Less predictive in non-transplant surgery Limited availability, cost

Table 2: Predictive Performance for Post-Hepatectomy Liver Failure (PHLF)

Test / Score Typical Cut-off for Major Resection Sensitivity Range Specificity Range Key Supporting Study (Example)
ICG-R15 >10-15% 70-85% 65-80% Imamura et al., J Hepatobiliary Pancreat Surg (2003)
ICG-PDR <15-18 %/min 75-90% 70-82% de Liguori Carino et al., HPB (2009)
Child-Pugh Score Class B or C High for severe dysfunction Moderate Widely adopted clinical standard
MELD Score >10-11 60-75% for PHLF 70-78% Schroeder et al., Ann Surg (2006)
LiMAx Test <315 µg/kg/h 89-94% 75-88% Stockmann et al., Gut (2010)

Detailed Experimental Protocols

Protocol 3.1: Standard ICG Clearance Test (PDR/R15 Measurement)

Objective: Determine the Plasma Disappearance Rate (PDR) and/or the 15-minute retention rate (R15) of ICG. Principle: ICG is exclusively taken up by hepatocytes and excreted unchanged into bile. Its concentration decay in blood is measured.

Materials & Reagents:

  • Indocyanine Green (ICG) powder, sterile.
  • Sterile water for injection.
  • Spectrophotometric analyzer or pulse densitometry device (e.g., LIMON).
  • Central or peripheral venous catheter.
  • Timer.

Procedure:

  • Preparation: Dissolve ICG powder in sterile water to a standard concentration (typically 5 mg/mL). Prepare a weight-based dose (typically 0.5 mg/kg body weight). Shield solution from light.
  • Baseline: Place optical sensor on patient's finger/nose or prepare blood sampling hub.
  • Injection: Rapidly inject the prepared ICG bolus intravenously. Start timer.
  • Measurement (Transcutaneous):
    • Using a pulse densitometer, continuously monitor the decreasing ICG concentration in the blood via optical density at 805 nm for at least 15 minutes.
    • The device software automatically calculates the PDR (normally >18 %/min) and R15 (normally <10%).
  • Measurement (Blood Sampling - Gold Standard):
    • Draw blood samples at precise times: pre-injection (blank), and at 5, 10, 15, and 20 minutes post-injection.
    • Centrifuge samples to obtain plasma.
    • Measure plasma absorbance spectrophotometrically at 805 nm against the blank.
    • Plot concentration vs. time on a semi-logarithmic scale. The slope of the linear decay phase is used to calculate PDR. R15 is derived from the concentration at 15 min relative to the theoretical initial concentration.
  • Analysis: Use the mono-exponential decay formula: Ct = C0 × e-kt, where PDR = k × 100.

Protocol 3.2: LiMAx Test Protocol

Objective: Quantify maximum liver function capacity via 13C-methacetin exhalation. Principle: The hepatocyte-specific enzyme CYP1A2 cleaves injected 13C-methacetin into 13C-labeled CO2, which is exhaled and measured.

Materials & Reagents:

  • 13C-methacetin solution (2 mg/kg body weight).
  • Breath analyzer (e.g., FANci).
  • Nasal breath sampler.
  • Calibration gas.

Procedure:

  • Patient Preparation: Overnight fasting. No smoking. Baseline breath sample collected.
  • Substrate Administration: Precisely inject 13C-methacetin intravenously.
  • Breath Sampling: The patient breathes normally into a nasal sampler connected to the analyzer. The 13CO2/12CO2 isotope ratio is measured in real-time for up to 60 minutes.
  • Data Calculation: The device software integrates the dose of administered 13C and the cumulative recovery in exhaled air over time, calculating the maximum enzymatic conversion rate (LiMAx value in µg/kg/h).

Protocol 3.3: Child-Pugh & MELD Score Calculation Protocol

Objective: Calculate prognostic scores from routine clinical data.

Procedure for Child-Pugh:

  • Data Collection: Obtain values for five parameters: Serum bilirubin, serum albumin, INR/prothrombin time, presence of ascites, presence of hepatic encephalopathy.
  • Grading: Assign points (1, 2, or 3) for each parameter based on severity thresholds.
  • Summation: Sum points. Class A: 5-6 points. Class B: 7-9 points. Class C: 10-15 points.

Procedure for MELD:

  • Data Collection: Obtain serum bilirubin (mg/dL), INR, and serum creatinine (mg/dL).
  • Calculation: Use the formula: MELD = 3.78 × ln[serum bilirubin (mg/dL)] + 11.2 × ln[INR] + 9.57 × ln[serum creatinine (mg/dL)] + 6.43.
  • Interpretation: Scores are rounded to the nearest whole number. Higher scores indicate higher 3-month mortality risk.

Visualizations

G Liver Function Assessment Modality Decision Pathway Start Patient: Liver Disease / Planned Resection CP Child-Pugh Score Start->CP MELD MELD Score Start->MELD ICG ICG Clearance Test (PDR, R15) CP->ICG Class B or Borderline A A1 Outpatient Management & Medical Therapy CP->A1 Class A A2 Transplant Evaluation & Listing CP->A2 Class C MELD->ICG Score ≤15 MELD->A2 Score >15 LiMAx LiMAx Test ICG->LiMAx Borderline or Complex Case ICG->A1 R15 >20% PDR <10%/min A3 Individualized Resection Planning ICG->A3 R15 10-20% PDR 10-18%/min LiMAx->A1 LiMAx <140 µg/kg/h LiMAx->A3 LiMAx 140-315 µg/kg/h A4 Safe Major Hepatectomy or ALPPS Decision LiMAx->A4 LiMAx >315 µg/kg/h

Title: Decision Pathway for Liver Function Modalities

G ICG & LiMAx: From Molecule to Measured Signal cluster_ICG ICG Clearance Pathway cluster_LiMAx LiMAx Metabolic Pathway ICG_Inj IV Bolus Injection of ICG Dye ICG_Blood Binding to Plasma Proteins (Albumin, Lipoproteins) ICG_Inj->ICG_Blood ICG_Uptake Active Transport into Hepatocytes (OATP1B3) ICG_Blood->ICG_Uptake ICG_Excrete Excretion into Bile (No Conjugation, MRP2) ICG_Uptake->ICG_Excrete ICG_Measure Measurement: Blood Concentration Decay @805 nm ICG_Excrete->ICG_Measure ICG_Output Output: PDR (%/min) R15 (%) ICG_Measure->ICG_Output LiMAx_Inj IV Injection of 13C-Methacetin LiMAx_Uptake Hepatocyte Uptake LiMAx_Inj->LiMAx_Uptake LiMAx_Enzyme Enzymatic Cleavage by CYP1A2 LiMAx_Uptake->LiMAx_Enzyme LiMAx_Prod Production of 13C-CO2 LiMAx_Enzyme->LiMAx_Prod LiMAx_Exhale Exhalation via Lungs LiMAx_Prod->LiMAx_Exhale LiMAx_Measure Measurement: 13CO2/12CO2 Isotope Ratio in Breath LiMAx_Exhale->LiMAx_Measure LiMAx_Output Output: Maximum Capacity (µg/kg/h) LiMAx_Measure->LiMAx_Output

Title: Biochemical Pathways of ICG and LiMAx Tests

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Liver Function Assessment Research

Item / Reagent Function / Application in Research Example / Specification
ICG (Indocyanine Green) The standard tracer for dynamic liver function tests. Used to calculate PDR and R15. Must be light-protected. Diagnostic Green, Inc. (e.g., IC-GREEN). Purity >95%.
13C-Methacetin The stable isotope-labeled substrate for the LiMAx test, metabolized by CYP1A2. Euriso-Top or Cambridge Isotope Laboratories. Chemical purity >99%, isotopic enrichment >99%.
Pulse Densitometer Non-invasive device for transcutaneous real-time measurement of ICG concentration decay. e.g., LIMON (PULSION Medical Systems). Measures at 805 and 905 nm.
13C Breath Analyzer Real-time isotope-selective spectrometer for measuring 13CO2 in exhaled breath. e.g., FANci (FAN GmbH). Provides online breath 13C/12C ratios.
Spectrophotometer & Cuvettes For precise in vitro measurement of ICG plasma concentrations from drawn blood samples (gold standard). UV-Vis Spectrophotometer capable of 805 nm measurement. Quartz or disposable plastic cuvettes.
Human Serum Albumin (HSA) Used in in vitro experiments to study ICG-protein binding kinetics and its impact on clearance. Fatty acid-free, >99% purity (Sigma-Aldrich).
CYP1A2 Inhibitors/Inducers Pharmacological tools to modulate CYP1A2 activity in preclinical models, validating LiMAx specificity. e.g., Fluvoxamine (inhibitor), Omeprazole (inducer).
Cell Culture Models Human hepatoma cell lines (HepG2, Huh7) or primary human hepatocytes for in vitro uptake studies. Cryopreserved Primary Human Hepatocytes (e.g., Thermo Fisher).
OATP1B3 / MRP2 Antibodies For immunohistochemistry or Western blot to correlate transporter expression with ICG test results. Validated monoclonal antibodies from suppliers like Abcam or Santa Cruz.
Liver Perfusion Systems Ex vivo or isolated organ setups to study the isolated impact of blood flow on ICG clearance. Precision-controlled peristaltic pumps and oxygenators.

Application Notes: ICG Metrics as Prognostic Biomarkers

Within the broader research on indocyanine green (ICG) for quantitative liver function assessment and surgical planning, a critical focus is the clinical validation of derived metrics against hard postoperative endpoints. Recent studies consistently demonstrate that dynamic ICG testing provides superior predictive value for postoperative liver failure (POLF), morbidity, and overall survival compared to static volumetric assessment alone.

Key Validated ICG Metrics:

  • ICG Plasma Disappearance Rate (ICG-PDR or ICG-R15): The percentage of ICG retained in plasma at 15 minutes post-injection. This is the most widely validated single metric.
  • ICG Clearance (ICG-K): The elimination rate constant, derived from the mono-exponential decay of ICG concentration.
  • Future Liver Remnant (FLR) Function: Calculated as Total ICG-K (or 1/R15) x (FLR volume / Total liver volume), integrating both function and anatomy.

Current literature, including meta-analyses from 2023-2024, confirms strong, independent correlations between these metrics and outcomes following major hepatectomy and hepatocellular carcinoma (HCC) resection.

Table 1: Summary of Clinical Validation Data for Key ICG Metrics

ICG Metric Predictive Threshold Correlated Outcome Reported Effect Size (Recent Studies) Clinical Utility
ICG-R15 >10% (Normal Liver) Post-Hepatectomy Liver Failure (PHLF) Odds Ratio: 3.2-5.1 Pre-op risk stratification. Contraindication for major resection if >20-30%.
>20% (Cirrhotic Liver) 90-Day Mortality Hazard Ratio: ~2.8 Guides extent of safe resection.
ICG-PDR <18%/min Severe Complications (Clavien-Dindo ≥III) Relative Risk: 2.5-3.0 Dynamic, real-time assessment. Lower values indicate impaired clearance.
FLR-ICG-K <0.05/min Liver Dysfunction & Prolonged Stay Sensitivity: ~85%, Specificity: ~80% Predicts function of remnant liver, superior to FLR volume alone.
ICG-K (Total) <0.12/min Overall Survival (HCC) 5-yr OS: 65% (≥0.12) vs. 40% (<0.12) Independent prognostic factor in cirrhotic HCC patients.

Detailed Experimental Protocols

Protocol 1: Standardized Dynamic ICG Clearance Test for Preoperative Assessment

Objective: To obtain ICG-PDR and ICG-R15 for baseline liver function quantification.

Materials & Reagents:

  • ICG dye (Diagnogreen or equivalent), 25 mg vials.
  • Dynamic Liver Function Monitor (e.g., LiMON, Pulsoflex).
  • Normal saline (0.9% NaCl).
  • Optical probe (finger or nasal sensor).
  • Data acquisition software.

Procedure:

  • Patient Preparation: Patient rests in supine position. Record weight. Establish IV access.
  • Dose Preparation: Reconstitute 25 mg ICG in 10 mL sterile water. Draw weight-based dose (0.25-0.5 mg/kg) into a syringe.
  • Baseline Measurement: Place optical probe on finger. Start monitoring and record a stable baseline for ≥60 seconds.
  • ICG Administration: Rapidly inject the ICG bolus via peripheral or central vein, followed immediately by a 10 mL saline flush.
  • Data Acquisition: Monitor continuously for 15-20 minutes. Ensure minimal patient movement.
  • Data Analysis: Software fits decay curve. Primary outputs: ICG-PDR (%/min) and ICG-R15 (%). Calculate ICG-K using: K = PDR / (100 * ln(10)).

Protocol 2: Intraoperative ICG Fluorescence Imaging for Resection Margin and Perfusion Assessment

Objective: To visually assess liver perfusion and biliary drainage in real-time to guide resection and predict remnant function.

Materials & Reagents:

  • Near-Infrared (NIR) fluorescence imaging system (e.g., Quest, PINPOINT).
  • ICG dye.
  • Sterile saline.

Procedure:

  • Pre-Injection Imaging: Perform a baseline white-light and NIR imaging of the surgical field.
  • ICG Administration: Inject 2.5 - 5.0 mg ICG IV after induction of anesthesia or during parenchymal transection.
  • Perfusion Phase Imaging (Immediate): Switch to NIR mode. Observe the homogeneous inflow of ICG into the liver parenchyma within 1-2 minutes. Poor or heterogeneous inflow suggests compromised vascular inflow.
  • Parenchymal Transection Guidance: Use real-time fluorescence to identify avascular planes and avoid major ducts/vessels.
  • Biliary Phase Imaging (Delayed, ~30-60 min): After major parenchymal division, re-image the cut surface. Focal areas of hyperfluorescence indicate possible biliary leakage from injured ducts.
  • Remnant Liver Evaluation: Assess uniform fluorescence of the future liver remnant as a qualitative marker of adequate perfusion and function.

Visualization: ICG Validation Workflow & Prognostic Pathways

G cluster_preop Preoperative Phase cluster_intraop Intraoperative Phase cluster_postop Postoperative Outcomes A Patient: Cirrhosis/HCC B Administer ICG Bolus A->B C Non-invasive Monitoring B->C D Calculate ICG-PDR & R15 C->D F Calculate FLR Function (FLR-ICG-K) D->F Combined with I 90-Day & Overall Survival D->I Prognostic for E FLR Volumetry (CT/MRI) E->F G PHLF (ISGLS Grade) F->G Predicts H Major Complications (Clavien-Dindo ≥III) F->H Predicts

Title: ICG Metric Clinical Validation Workflow

G ICG Impaired ICG Clearance (Low PDR, High R15) Hepato Hepatocellular Dysfunction (Reduced Mass/Function) ICG->Hepato Indicates Portal Portal Hemodynamics (Shunting, Hypertension) ICG->Portal Reflects Synthesis ↓ Protein Synthesis (Clotting Factors) Hepato->Synthesis Leads to Detox ↓ Metabolic/Detox Capacity Hepato->Detox Leads to Regeneration ↓ Regenerative Capacity Portal->Regeneration Impairs PHLF Post-Hepatectomy Liver Failure Synthesis->PHLF Collectively Cause Regeneration->PHLF Collectively Cause Detox->PHLF Collectively Cause Mortality Increased Mortality PHLF->Mortality Drives

Title: Pathophysiological Link: ICG to Liver Failure

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Materials for ICG Functional Assessment Research

Item Function / Role in Research
ICG-Dye (Sterile) The fluorescent probe. Its exclusive hepatic uptake and biliary excretion is the basis for all metrics. Must be protected from light.
Dynamic Bedside Monitor (LiMON/Pulsoflex) Enables real-time, non-invasive pulse spectrophotometric measurement of ICG concentration in blood for PDR/R15 calculation.
NIR Fluorescence Imaging System For intraoperative visualization of liver perfusion, biliary anatomy, and tumor detection. Provides qualitative functional data.
HPLC-Validated ICG Standard Essential for calibrating in-house assays or validating monitor accuracy in pharmacokinetic studies.
Liver-Specific Cell Culture Media For in vitro studies on ICG uptake (via OATP1B1/1B3 transporters) in hepatocyte cell lines under various conditions.
Animal Model (e.g., Rat PHx, Mouse CCl4) Preclinical models of liver regeneration or fibrosis to correlate ICG clearance with histological and molecular biomarkers.
Data Analysis Software (e.g., MATLAB, R) For custom pharmacokinetic modeling, statistical correlation with outcomes, and generating survival curves (Kaplan-Meier).

This application note frames the comparative analysis of Indocyanine Green (ICG), Contrast-Enhanced Ultrasound (CEUS), and Augmented Reality (AR) within the specific thesis context of developing quantitative ICG imaging for precise liver functional assessment and real-time resection guidance. While AR provides structural roadmaps and CEUS offers real-time vascular perfusion, the central thesis posits that ICG fluorescence, through pharmacokinetic modeling of its hepatic uptake and excretion, can uniquely provide a spatially resolved, quantitative map of function. The objective is to define protocols that integrate or contrast these modalities to validate ICG-derived functional metrics against established techniques and anatomical overlays.

Table 1: Core Technical and Functional Characteristics

Parameter ICG Fluorescence Imaging Contrast-Enhanced Ultrasound (CEUS) Augmented Reality (AR) Navigation
Primary Physical Principle Near-infrared fluorescence (Ex: ~800 nm) Ultrasound backscatter from microbubbles Optical/electromagnetic tracking & 3D registration
Key Assessable Parameter Functional: ICG clearance rate, retention at 15 min (ICG-R15), biliary excretion. Anatomical: Real-time bile duct visualization, tumor detection via fluorescence defect. Hemodynamic: Tissue perfusion parameters (Time-Intensity Curves: Peak Intensity, Time-to-Peak, Mean Transit Time). Vascular architecture. Anatomical: 3D spatial relationship of tumors, vessels, and resection planes to the intraoperative situs.
Spatial Resolution High (sub-mm to mm, surface-weighted) Moderate (mm-scale, depth-dependent) High (depends on pre-op imaging, e.g., CT/MRI)
Temporal Resolution Moderate (seconds to minutes for kinetics) Very High (real-time, frame-by-frame perfusion) Static (updated upon manual registration or with trackers)
Penetration Depth Superficial (~5-10 mm in tissue) Deep (entire organ, depth ~cm) Surface projection only
Quantification Maturity Research focus: Kinetics for function. Semi-quantitative tumor/background ratio. Clinical: Established quantitative perfusion software (Qontrast). Geometric: Accuracy of registration (Target Registration Error in mm).
Primary Clinical Use in Liver Bile duct imaging, tumor detection, lymphatic mapping. Lesion characterization, ablation monitoring, vascular complications. Guidance for complex anatomic resections.
Role in Functional Thesis Primary Investigational Modality for creating functional liver maps. Validation Tool for regional perfusion vs. ICG uptake kinetics. Anatomical Framework for projecting functional (ICG) maps onto the surgical field.

Table 2: Quantitative Performance Metrics from Recent Studies (2020-2024)

Study Focus ICG Performance CEUS Performance AR Performance Key Finding for Thesis
Tumor Detection Sensitivity 85-92% for colorectal liver metastases (additional subcapsular lesions) 89-95% for hepatocellular carcinoma (HCC) characterization N/A (anatomical guidance) ICG complements B-mode ultrasound for superficial metastases missed by pre-op imaging.
Functional Assessment Metric ICG-R15 correlates with future liver remnant (FLR) function (r=0.78, p<0.01). Portal venous perfusion in FLR predicts post-hepatectomy liver failure (AUC=0.82). N/A ICG-R15 and CEUS perfusion provide correlative but distinct functional data (cellular vs. vascular).
Registration/Accuracy N/A N/A Target Registration Error (TRE): 3-10 mm in clinical settings. AR error margin must be considered when overlaying high-resolution ICG functional maps.

Detailed Experimental Protocols

Protocol 1: Intraoperative ICG Fluorescence Kinetics for Regional Liver Function Mapping

Objective: To acquire quantitative ICG fluorescence time-series data from different liver segments for spatial function assessment.

Materials: See "Scientist's Toolkit" (Table 3).

Pre-operative:

  • Obtain patient consent and measure body weight.
  • Calculate ICG dose: 0.25 mg/kg body weight.
  • Prepare ICG solution: Reconstitute 25 mg ICG in 10 ml sterile water. Dilute to the exact calculated dose in a 10 ml syringe.

Intraoperative Imaging Workflow:

  • After laparotomy and liver mobilization, position the fluorescence imaging system (e.g., PDE, FLARE, or research-grade systems like the Quest Spectrum) ~30-50 cm above the liver surface.
  • Baseline Acquisition: Record a 30-second video of the native tissue autofluorescence (Ex: 760 nm, Em: 830 nm, exposure time fixed).
  • ICG Administration: Inject the prepared ICG dose as a rapid intravenous bolus via a central or peripheral line. Start a synchronized timer.
  • Data Acquisition: Continuously record fluorescence video for at least 15 minutes post-injection. Ensure the camera field of view is stable and includes anatomical landmarks.
  • Biliary Phase Imaging: At 60-90 minutes post-injection, capture static high-exposure images to visualize the biliary tree.

Data Analysis:

  • ROI Definition: Using post-processing software (e.g., ImageJ, OsiriX, or custom MATLAB/Python scripts), define Regions of Interest (ROIs) over distinct Couinaud segments.
  • Kinetic Curve Extraction: For each ROI and each video frame, extract mean fluorescence intensity (FI). Plot FI vs. Time.
  • Parameter Calculation:
    • Tmax: Time to maximum fluorescence intensity.
    • Uptake Slope: Initial slope of the FI curve (approx. 0-3 mins).
    • Clearance Rate: Exponential decay constant after Tmax.
    • Relative ICG-R15: Calculate (FI at 15min / FI at Tmax) * 100% for each ROI.

ICG_Kinetics_Workflow PreOp Pre-op: ICG Dose Calculation (0.25 mg/kg) Prep Prepare ICG Solution (Reconstitute & Dilute) PreOp->Prep Baseline Intraop: Acquire Baseline Autofluorescence Video Prep->Baseline Inject Bolus IV Injection of ICG (Start Timer t=0) Baseline->Inject Record Continuous NIR Video Acquisition (t=0 to t≥15 min) Inject->Record Biliary Late Phase Imaging (t=60-90 min) for Biliary Tree Record->Biliary Analysis1 Post-processing: Define ROIs over Liver Segments Record->Analysis1 Analysis2 Extract Mean Fluorescence Intensity vs. Time Analysis1->Analysis2 Analysis3 Calculate Kinetic Parameters: Tmax, Uptake Slope, Clearance, ICG-R15 Analysis2->Analysis3 Output Output: Regional Functional Liver Map Analysis3->Output

Diagram Title: ICG Liver Function Imaging Experimental Workflow

Protocol 2: Intraoperative CEUS for Perfusion Validation of ICG Findings

Objective: To validate regional ICG uptake patterns with quantitative CEUS perfusion parameters in the same liver segments.

Materials: Ultrasound system with CEUS capability, low-mechanical-index (MI) contrast-specific imaging mode, sulfur hexafluoride microbubbles.

Protocol:

  • After ICG imaging, position the ultrasound transducer (e.g., convex 1-6 MHz) on the liver surface using a sterile cover.
  • Baseline Scan: Identify the same anatomical segments imaged with ICG.
  • Contrast Administration: Prepare a 2.4 ml bolus of microbubble contrast. Inject intravenously followed by a 10 ml saline flush.
  • Data Acquisition: Start the ultrasound system's internal timer upon injection. Using a low MI (<0.2), record a cine loop in contrast-specific mode (e.g., Cadence Contrast Pulse Sequencing) for 2-3 minutes, holding the probe as stable as possible.
  • Repeat for different liver segments as needed.

Analysis:

  • Using dedicated quantification software, place ROIs matching the ICG analysis locations.
  • Generate Time-Intensity Curves (TIC).
  • Extract perfusion parameters: Peak Enhancement (PE, dB), Time-to-Peak (TTP, sec), Area Under the Curve (AUC).
  • Correlative Analysis: Perform linear regression between ICG uptake slope (from Protocol 1) and CEUS-derived PE or AUC in the same segment.

CEUS_Validation_Protocol Start Post-ICG Imaging Position Position US Transducer on Sterile Liver Surface Start->Position Align Align US View with ICG-imaged Segments Position->Align InjectCEUS Bolus IV Injection of Microbubble Contrast Agent Align->InjectCEUS RecordCine Record Low-MI Cine Loop (2-3 minutes, stable probe) InjectCEUS->RecordCine Quantify Quantitative TIC Analysis: Place Matching ROIs RecordCine->Quantify Params Extract Perfusion Parameters: PE, TTP, AUC Quantify->Params Correlate Correlate CEUS Parameters with ICG Kinetics (e.g., Uptake Slope) Params->Correlate

Diagram Title: CEUS-ICG Correlation Analysis Protocol

Protocol 3: AR Overlay of ICG Functional Data on Surgical Field

Objective: To project a pre-operatively segmented 3D model, annotated with intraoperative ICG functional data, onto the patient's liver via an AR headset.

Materials: Pre-operative CT/MRI, 3D segmentation software, AR headset (e.g., HoloLens 2), optical tracking system.

Pre-operative Workflow:

  • Segment the liver, tumors, and key vasculature from pre-op CT using software (e.g., 3D Slicer).
  • Export the 3D model in a compatible format (e.g., .glb, .fbx).

Intraoperative Registration & Overlay:

  • Point-Pair Registration: After laparotomy, use a tracked pointer to touch anatomical landmarks (e.g., vessel bifurcations) on the actual liver surface.
  • Match these points to corresponding points on the 3D virtual model in the AR system software.
  • The system calculates the transformation, yielding a Target Registration Error (TRE).
  • ICG Data Fusion: Import the 2D functional map from Protocol 1. Using the registered 3D model as a geometric scaffold, map the ICG kinetic parameters (e.g., ICG-R15) onto the corresponding virtual liver segments using a color-coded scheme (e.g., green=normal, red=impaired).
  • AR Visualization: The surgeon, wearing the AR headset, sees the color-coded functional map projected as a semi-transparent overlay directly onto the physical liver.

AR_ICG_Fusion PreOpSeg Pre-op: Segment Liver, Tumors, Vessels from CT/MRI LandmarkReg Intraop Point-Pair Registration: Physical Landmarks → 3D Model PreOpSeg->LandmarkReg ICGData Intraop: Acquire Quantitative ICG Functional Map (Protocol 1) Fuse Fuse ICG Functional Data onto Registered 3D Model ICGData->Fuse CalcTRE Calculate Target Registration Error (TRE) LandmarkReg->CalcTRE CalcTRE->Fuse Project AR Headset Projects Color-coded Functional Overlay Fuse->Project

Diagram Title: AR Overlay of ICG Functional Data

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Materials for ICG-Based Liver Function Research

Item Function/Description Example Brand/Product (Research-Grade)
ICG, Sterile The fluorophore for functional imaging. Must be pharmaceutical grade for human use; research-grade for animal models. PULSION (Diagnostic Green for clinical), Sigma-Aldrich (for preclinical).
NIR Fluorescence Imaging System Camera system capable of exciting (~760 nm) and detecting (~830 nm) ICG fluorescence with quantitative capability (stable exposure, radiometric calibration). Quest Spectrum (Q2, research customizable), FLARE (open-source platform), Hamamatsu PDE (clinical).
Quantitative Analysis Software Software for time-series analysis of fluorescence intensity, ROI management, and kinetic parameter extraction. ImageJ/Fiji (with custom macros), 3D Slicer (IGSTK module), Custom MATLAB/Python scripts.
Ultrasound System with QCEUS Ultrasound machine equipped with contrast-specific imaging modes and quantitative perfusion analysis software. Siemens Acuson (with Qontrast), Canon Aplio (with HI-RTE), BK Medical (with UroNav).
Microbubble Contrast Agent Ultrasound contrast agent for CEUS perfusion studies. SonoVue (Bracco), Definity (Lantheus).
AR/Navigation Platform System for 3D model registration and overlay onto the surgical field. Microsoft HoloLens 2, Medivis SurgicalAR, Proprietary research platforms (e.g., using OpenIGTLink).
Optical Tracking System Tracks instruments and the patient for registration in AR/navigation. NDI Polaris, Atracsys fusionTrack.
3D Segmentation Software Creates 3D models from DICOM images for AR and planning. 3D Slicer (open-source), Materialise Mimics.
Calibration Phantom (NIR) For quantifying and calibrating fluorescence signal (converting intensity to [ICG]). Homogeneous epoxy phantoms with known ICG concentration, Radiometric calibration targets.

The Evolving Role of ICG in the Era of Radiomics, Artificial Intelligence, and Personalized Surgical Planning

Application Notes

Indocyanine green (ICG) fluorescence imaging has transitioned from a purely qualitative surgical navigation tool to a quantitative biomarker integrated within multi-modal data frameworks. In the context of liver function assessment and precision resection planning, ICG pharmacokinetics (ICG-PK) now serves as a critical in vivo functional dataset. When combined with radiomic features extracted from CT/MRI and analyzed through machine learning (ML) pipelines, ICG enables the creation of patient-specific liver functional maps. These maps predict postoperative liver remnant (FLR) function with superior accuracy compared to volumetric assessment alone, directly addressing the core challenge of preventing post-hepatectomy liver failure (PHLF). For drug development, particularly in oncology, ICG-based functional imaging provides a real-time, non-invasive modality to monitor drug-induced liver injury (DILI) and assess regional hepatocyte function in response to targeted therapies, offering a bridge between preclinical models and clinical outcomes.

Quantitative Data Synthesis

Table 1: Key Quantitative Metrics from Recent ICG-Radiomics-AI Integration Studies

Study Focus Cohort Size (n) Key Metric (Control vs. Model) AI Model Performance (AUC) Clinical Endpoint Correlation (r/p-value)
PHLF Prediction 215 ICG-PK (R15) + Volumetry vs. +Radiomics+ML 0.83 vs. 0.94 PHLF Grade B/C, p<0.001
Functional Liver Segmentation 142 Correlation: ICG Clearance vs. Radiomic Texture N/A r = 0.78, p<0.001
Metastasis Function Mapping 87 Perilesional Function Loss Quantification N/A 15-40% function loss within 2cm rim
DILI Monitoring (Preclinical) 48 (rats) ICG Clearance Delay vs. Histology Score 0.91 (for severe DILI) r = 0.85, p<0.001

Detailed Experimental Protocols

Protocol 1: Integrated ICG-PK and CT Radiomics for FLR Function Prediction

Objective: To generate a machine learning model that predicts post-resection liver function by fusing ICG pharmacokinetic data with CT radiomic features.

Materials:

  • ICG-PK measurement system (e.g., LIMON, PDE-Neo)
  • Preoperative contrast-enhanced CT scans (portal venous phase)
  • Serum biochemistry analyzer
  • AI/ML software platform (e.g., Python with scikit-learn, PyRadiomics library)

Procedure:

  • ICG Pharmacokinetics:
    • Administer ICG intravenously at 0.5 mg/kg body weight.
    • Acquire real-time fluorescence intensity data via a surface probe or imaging system over 15 minutes.
    • Calculate PK parameters: Plasma disappearance rate (ICG-PDR, %/min), retention rate at 15 minutes (ICG-R15, %), and blood clearance half-life (T1/2).

  • Image Processing and Segmentation:

    • Register preoperative CT scans with 3D ICG fluorescence intensity maps (if available) or functional volumetric data.
    • Semi-automatically segment the total liver, future liver remnant (FLR), and tumor(s) using dedicated software (e.g., 3D Slicer).
    • For the FLR and non-FLR parenchyma, extract a standardized panel of 121 radiomic features (first-order statistics, shape, texture - GLCM, GLRLM, GLSZM) using the PyRadiomics pipeline.

  • Data Fusion and Model Building:

    • Create a unified feature vector per patient: [ICG-PDR, ICG-R15, FLR Volume %, 5 key radiomic features (e.g., Entropy, Kurtosis)].
    • Split dataset (e.g., 70/30) into training and validation sets.
    • Train a Random Forest or Gradient Boosting classifier to predict a binary outcome (e.g., adequate vs. inadequate FLR function, defined by post-op biochemical criteria).
    • Validate model performance using ROC-AUC, precision, recall on the hold-out set.

  • Output: A patient-specific risk score and a visual functional map overlaid on the CT anatomy, highlighting regions of impaired ICG uptake/clearance.

Protocol 2: ICG as a Biomarker for Drug-Induced Liver Injury (DILI) in Preclinical Models

Objective: To quantify spatial and temporal changes in hepatic function in a rodent model of drug-induced liver injury using dynamic ICG imaging.

Materials:

  • Small animal fluorescence molecular tomography (FMT) system or planar imaging system.
  • Rodent model of DILI (e.g., acetaminophen-induced).
  • ICG for injection.
  • Histology supplies (H&E, ALT/AST assay kits).

Procedure:

  • Baseline Imaging:
    • Anesthetize and stabilize the animal in the imaging system.
    • Administer ICG (2.5 mg/kg) via tail vein.
    • Acquire dynamic fluorescence images sequentially for 20 minutes. Use a region-of-interest (ROI) analysis to generate a baseline time-intensity curve for the whole liver.

  • Induction and Longitudinal Monitoring:

    • Administer the hepatotoxic agent.
    • Repeat the dynamic ICG imaging at predetermined time points (e.g., 6h, 24h, 48h post-dose).
    • Calculate ICG clearance half-life (T1/2) and normalized fluorescence intensity at peak and 15-min post-injection for each time point.

  • Correlation with Traditional Biomarkers:

    • At terminal time points, collect blood for serum ALT/AST measurement.
    • Harvest liver for histological scoring (e.g., necrosis area percentage).
    • Perform correlation analysis between imaging metrics (ΔICG T1/2) and serum/histology scores.

  • Output: Kinetics curves and parametric images showing regions of delayed clearance, providing a non-invasive, longitudinal functional assessment of DILI progression/regression.

Visualizations

ICG_AI_Workflow CT CT Segmentation Liver & Tumor Segmentation CT->Segmentation MRI MRI MRI->Segmentation ICG_PK ICG-PK Data (PDR, R15) Feature_Selection Feature Selection & Fusion ICG_PK->Feature_Selection Clin_Lab Clinical & Lab Data Clin_Lab->Feature_Selection Radiomics Radiomic Feature Extraction (n=121+) Segmentation->Radiomics Radiomics->Feature_Selection AI_Model AI/ML Model (e.g., Random Forest) Feature_Selection->AI_Model Training Set Output Personalized Surgical Plan: - Functional Risk Score - 3D Functional Map - Resection Guidance AI_Model->Output

Workflow for AI-Enhanced Surgical Planning

ICG_PK_Pathway ICG_Injection ICG_Injection Blood_Stream Blood_Stream ICG_Injection->Blood_Stream Hepatocyte_Uptake Hepatocyte_Uptake Blood_Stream->Hepatocyte_Uptake Bound to Albumin Biliary_Excretion Biliary_Excretion Hepatocyte_Uptake->Biliary_Excretion No Conjugation PK_Parameter_Node ICG-PDR ICG-R15 T1/2 Hepatocyte_Uptake->PK_Parameter_Node Feces Feces Biliary_Excretion->Feces Primary Route Biomarker Quantitative Biomarker For: - Global Liver Function - Regional Impairment - ATP-dependent Transport PK_Parameter_Node->Biomarker

ICG Pharmacokinetic Pathway & Biomarker

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Materials for ICG-based Functional Research

Item Function & Specification Key Consideration for Research
ICG for Injection The fluorescent tracer. High purity (>95%) is essential for reproducible PK. Use a single, validated batch for a longitudinal study. Protect from light. Reconstitute strictly per protocol.
Fluorescence Imaging System Quantifies spatial/temporal ICG distribution. Options: open systems (PDE-Neo), laparoscopic probes, small animal FMT. Ensure system linearity for quantification. Standardize imaging distance/parameters.
Pharmacokinetic Analysis Software Dedicated software (e.g., LiMON built-in, IC-CALC) or custom MATLAB/Python scripts to calculate PDR, R15, T1/2 from time-intensity data. Validate custom algorithms against clinical gold-standard outputs.
Medical Image Analysis Platform Software for segmentation & radiomics (e.g., 3D Slicer with TotalSegmentator, PyRadiomics; MITK; MeVisLab). Standardize segmentation protocols across researchers. Use fixed image pre-processing settings for radiomics.
Machine Learning Environment Platform for model development (e.g., Python with scikit-learn, TensorFlow/PyTorch; R with caret). Implement rigorous cross-validation. Prioritize model interpretability (SHAP values) for clinical translation.
Histology & Biochemistry Kits For ground truth validation (e.g., ALT/AST assays, H&E staining, ATP assay kits). Plan terminal timepoints to correlate ICG metrics with histopathological scoring.

Conclusion

ICG fluorescence imaging has evolved from a simple clearance test into an indispensable, multi-functional tool that bridges quantitative hepatology and precision surgery. It provides a dynamic, real-time assessment of liver function that surpasses static scoring systems, enabling personalized risk stratification and meticulous resection planning to minimize PHLF. While challenges in quantification and standardization persist, ongoing technological integration with AI and 3D reconstruction promises a future of even more predictive and patient-specific liver surgery. For researchers, ICG offers a robust functional endpoint for evaluating liver-targeted drugs and disease progression, solidifying its role as a cornerstone in both advanced clinical hepatology and translational biomedical research.